# University of California, San Francisco CURRICULUM VITAE

Name: Theodore W Kurtz, MD

**Position:** Professor In Residence, Step A/S

Laboratory Medicine School of Medicine

Address: Box 0134

185 Berry Street, Suite 290

University of California, San Francisco

San Francisco, CA 94107

Voice: 415-353-1979 Fax: 415-353-4851

Email: ted.kurtz@ucsf.edu

#### **EDUCATION**

1971 - 1975	University of Michigan	B.S.	Zoology
1975 - 1979	University of Michigan	M.D.	Medicine
1980 - 1982	Univ. of California, San Francisco	Resident	Laboratory Medicine
1982 - 1983	Univ. of California, San Francisco	Chief Resident	Laboratory Medicine

#### LICENSES, CERTIFICATION

1981 Medical licensure, California # G46628

1984 Certified, American Board of Pathology, Clinical Pathology

#### PRINCIPAL POSITIONS HELD

1983 - 1984	Univ. of California, San Francisco	Asst. Clinical Professor	Laboratory Medicine
1984 - 1987	Univ. of California, San Francisco	Asst. Professor in Residence	Laboratory Medicine
1987 - 1992	Univ. of California, San Francisco	Assoc. Professor in Residence	Laboratory Medicine
1992 - present	Univ. of California, San Francisco	Professor in Residence	Laboratory Medicine

#### OTHER POSITIONS HELD CONCURRENTLY

1985 - 1987	Univ. of California, San Francisco	Assistant	General Clinical
		Director	Research Center

1987 - present	UCSF Medical Center	Director	Clinical Chemistry Laboratories
1997 - 2021	Univ. of California, San Francisco	Vice-Chair	Laboratory Medicine
1998 - 2021	Univ. of California, San Francisco	Affiliate Faculty	Institute for Human Genetics
1999 - present	Univ. of California, San Francisco	Member	Cardiovascular Research Institute
2000 - 2002	American Society of Hypertension	President	

#### **HONORS AND AWARDS**

1975	James B. Angell Scholar	University of Michigan
1976	Outstanding Research Fellow	Michigan Heart Association
1979	Dean's Award for Research Excellence	University of Michigan
1993	Clinical Investigator Award	National Heart, Lung, and Blood Institute, NIH
1994	SmithKline Beecham Young Investigator Award	International Society of Hypertension
2000	President	American Society of Hypertension
2006	Novartis Award for Hypertension Research	American Heart Association, Council for High Blood Pressure Research
2010	International Okamoto Research Award	Japan Vascular Disease Research Foundation
2013	Outstanding Contributions to Clinical Chemistry in Education	Northern California Section, American Association of Clinical Chemistry

#### **KEYWORDS/AREAS OF INTEREST**

Molecular genetics, complex diseases, hypertension, salt sensitivity, metabolic syndrome, diabetes, cardiovascular disease, transgenic strains, congenic strains, conplastic strains, clinical chemistry, electrolyte metabolism

# **CLINICAL ACTIVITIES**

# **CLINICAL SERVICES**

1987 - present Medical Director and Clinical Attending, Clinical Chemistry Full time section of the UCSF Clinical Laboratories at Parnassus and China Basin

2014 - 2021	Member, Clinical Laboratory Compliance Committee covering UCSF Moffitt-Long, Mission Bay, and Mt Zion Medical Centers	Biannually
2014 - present	Member, Quality Improvement Committee, UCSF China Basin Clinical Laboratories	Quarterly
2014 - present	Member, Quality Improvement Committee, UCSF Parnassus Clinical Laboratory	Quarterly
2022 - present	Chair, Site-wide Chemistry Laboratory Committee, UCSF Clinical Laboratories	Biomonthly

# **PROFESSIONAL ACTIVITIES**

# **MEMBERSHIPS**

1985 - present American Society of Hypertension/American Heart Association Hypertension Council

1990 - present International Society of Hypertension

# **SERVICE TO PROFESSIONAL ORGANIZATIONS**

1996 - 2004	American Society of Hypertension	Member, Executive Council
1998 - 2000	American Society of Hypertension	President-Elect
1998 - 2005	American Society of Hypertension	Member, Scientific Program Committee
1998 - 2007	International Society of Hypertension	Member, Scientific Program Committee
1998 - 2001	American Heart Association, Western States Affiliate	Member, Research Committee
1998 - 2010	American Heart Association Council on Hypertension	Member, Abstract Grading Panel
2000 - 2002	American Society of Hypertension	President
2000 - 2004	American Society of Hypertension	Member, Finance Committee
2000 - 2001	International Society for Cardiovascular Endocrinology and Metabolism, Cairns, Australia	Member, Executive Board of Satellite Program Organizing Committee
2001 - 2003	American Heart Association Council on Hypertension	Member, Executive Committee

2001 - 2002	International Symposium on Obesity and Hypertension, Berlin	Member, Program Committee
2001 - 2002	International Symposium on SHR and Molecular Medicine, Berlin	Member, International Advisory Board
2001 - 2002	International Society of Hypertension Satellite Symposium on Genetics of Human and Experimental Hypertension	Member, Program Committee
2001 - 2003	American Society of Hypertension	Chair, Corporate Affairs Committee
2001 - 2003	American Society of Hypertension	Chair, Strategic Planning Committee
2002 - 2003	International Symposium on Atherosclerosis, Kyoto, Japan	Member, Organizing Committee
2003 - 2006	American Society of Hypertension	Chair, Chapter Relations Committee
2003 - 2004	American Society of Hypertension	Chair, Nominating Committee
2004 - 2006	American Society of Hypertension	Member, Nominating Committee
2004 - 2006	American Society of Hypertension	Member, Abstract Selection Committee
2005 - 2006	American Heart Association	Chair, Writing Group Committee on BP Measurements in Animal Models
2005 - 2006	American Heart Association	Member, Writing Group Committee on BP Measurements in Humans
2005 - 2006	American Society of Hypertension	Member, Finance Committee
2005 - 2006	International Society of Hypertension	Chair, Satellite Symposium on the Metabolic Syndrome
2006 - 2010	AHA Council for High Blood Pressure Research	Member, Novartis Awards Committee

2006 - 2007	International Symposium on the Metabolic Syndrome, Osaka, Japan	Chair, Organizing Committee
2014 - 2014	International Symposium on the Metabolic Syndrome, Osaka, Japan	Chair, Organizing Committee
2014 - 2014	International Society of Hypertension	Member, Abstract Grading Committee
2008 - 2016	International Symposium on the Metabolic Syndrome, Osaka, Japan	Member, Organizing Committee
2009 - 2016	American Society of Hypertension	Member, Abstract Grading Committee
2015 - 2017	Genetics/SHR Satellite Meeting of the International Society of Hypertension	Chair, Organizing Committee
2017 - 2018	American Heart Association	Member, Scientific Statement Writing Group Committee: Animal Models of Hypertension
2014 - 2023	International Meeting on the SHR: Etiology of Genetic Hypertension	Co-Chair, Organizing Committee
2011 - present	American Heart Association Council on Hypertension	Member, Abstract Grading Committee
2018 - present	American Heart Association Council on Hypertension	Member, Awards Selection Committee
2018 - present	Japan Research Foundation for Healthy Aging	Member, Awards Selection Committee

# SERVICE TO PROFESSIONAL PUBLICATIONS

1991 - present	Ad hoc referee for Nature, Science, Journal of Clinical Investigation; Am Journal of Physiology; Circulation, Circulation Research; American Journal of Hypertension; Cardiovascular Drugs and Therapy; Nature Genetics; Hypertension; Journal of Hypertension; Journal of Cardiovascular Pharmacology; Arteriosclerosis, Thrombosis, and Vascular Biology, Diabetes, New England Journal of Medicine, Hypertension Research, Clinical and Experimental Hypertension, Epigenetics, Trends in Cardiovascular Medicine, Scientific Reports, PLOS One, FEBS Letters, PNAS, Kidney International, Journal of the American Society of Nephrology
	Journal of the American Society of Nephrology
2003 - 2004	Secretary, American Journal of Hypertension
2000 - 2007	Editorial Board, American Journal of Hypertension

2005 - 2008	Editorial Board, Journal of Hypertension
2011 - 2012	Guest Editor, Experimental Diabetes Research
2014 - 2015	Member, Search Committee for Editor-in-Chief of the American Journal of Hypertension
1999 - 2016	Editorial Board, Physiological Genomics
1991 - present	Editorial Board, Hypertension
2009 - present	Associate Editor, Hypertension Research
2013 - present	Executive Board, American Journal of Hypertension
2014 - present	Treasurer, American Journal of Hypertension
INVITED PRES	SENTATIONS - INTERNATIONAL
2005	Invited Lecture: New Treatment Strategies for Hypertensive Patients with Insulin Resistance. Thailand Society of Hypertension, Bangkok, Thailand, Feb 18, 2005
2005	Invited Lecture: Treating Insulin Resistance, Hypertension and the Metabolic Syndrome. South African Society of Hypertension, Cape Town, South Africa, March 6, 2005
2005	Invited Lecture: New Approaches to Insulin Resistance and Hypertension. 15th Clinical Endocrine Metabolism Update, Sapporo, Japan, March 12, 2005
2005	Invited Lecture: Treating Insulin Resistance, Hypertension, and the Metabolic Syndrome. Division of Nephrology, Endocrinology, and Vascular Medicine, Sendai University, Sendai, Japan, March 14, 2005
2005	Invited Lecture: Selective PPAR Modulators That Block the Angiotensin II Receptor. 3rd International Symposium on PPARs, Monte Carlo, Monaco, March 23, 2005
2005	Invited Lecture: Metabolic Effects of ARBs Beyond Renin Angiotensin System Blockade: Are All Molecules the Same? Satellite Symposium of the German Society of Cardiology, Mannheim, Germany, April 1, 2005
2005	Invited Lecture: New Evidence for Antidiabetic Effects of Angiotensin Receptor Blockers. VIII International Forum on the Renin-Angiotensin System, Capri, Italy, April 15-16, 2005
2005	Invited Session Chair: Molecular Genetics of Hypertension. VIII International Forum on the Renin-Angiotensin System,

Capri, Italy, April 15-16, 2005

2005	Invited Lecture: Metabolic Effects of Inhibiting the Renin- Angiotensin System: New Perspectives. Boehringer- Ingelheim Symposium on Pharmacologic Therapy for Diabetes Mellitus and Arterial Hypertension: Fermo, Italy, April 27, 2005
2005	Invited Lecture: Antidiabetic Effects of Angiotensin Receptor Blockers. CME Course on Hypertension and Associated Risk Factors, Regello, Italy, April 28, 2005
2005	Invited Lecture: Metabolic Effects of Renin Angiotensin System Blockade. Medicine Grand Rounds, Hospital Maisonneuve-Rosemont, Montreal, Quebec, May 31, 2005
2005	Invited Lecture: Treatment of Insulin Resistance, Hypertension, and Metabolic Syndrome.Nephrology Grand Rnds, Hopital Notre Dame, Univ of Montreal, Quebec, May 31, 2005
2005	Invited Lecture: New Approaches to Insulin Resistance, Hypertension, and the Metabolic Syndrome. Medicine Grand Rounds, Hopital Fleurimont, Sherbrooke, Canada, June 1, 2005
2005	Invited Lecture: Treatment of Insulin Resistance, Hypertension, and the Metabolic Syndrome. Cardiology Grand Rounds, the Royal Victoria Hospital and University of Montreal, Montreal, Canada, June 2,
2005	Invited Lecture: New Approaches to Hypertension and the Metabolic Syndrome. Medicine Grand Rounds, the Jewish General Hospital, Montreal, Quebec, June 2, 2005
2005	Invited Lecture: Antidiabetic Effects of Angiotensin Receptor Blockers. Satellite Symposium of the European Society of Cardiology. Stockholm, Sweden, Sept 6, 2005
2005	Invited Lecture: New Treatment Strategies for Hypertensive Patients with Insulin Resistance. Cardiology Grand Rounds, London Health Sciences, University Campus, London, Ontario, Sept 26, 2005
2005	Invited Lecture: Antidiabetic Effects of ARBs: Are All Molecules the Same? Internal Medicine Grand Rounds, London Health Sciences, Victoria Campus, London, Ontario, Sept 26, 2005
2005	Invited Lecture: Metabolic Benefits of Antihypertensive Therapy Beyond AT1 Receptor Blockade, 7th Meeting on Diabetes and Cardiovascular Risk Factors, Hong Kong, October 2, 2005

2005	Invited Lecture: Antidiabetic Effects of ARBs: Are All Molecules the Same? Research Seminar, Osaka University Graduate School of Medicine, Osaka, Japan, October 12, 2005
2005	Plenary Lecture: Obesity, Insulin Resistance, and Hypertension. Japan Society for the Study of Obesity, Sapporo, Japan, October 14, 2005
2005	Invited Lecture: New Treatment Strategies for Hypertensive Patients with Insulin Resistance. International Symposium on Cardiovascular Protection, Rio de Janeiro, Brazil, October 22, 2005
2006	Invited Lecture: Treating Insulin Resistance in the Hypertensive Patient. French Society of Cardiology, Paris, France, January 20, 2006
2006	Invited Lecture: New Findings in Metabolic Disorders and the Role of PPAR gamma:Are all ARBs the Same? Spanish Society of Hypertension, Madrid, Spain, March 10, 2006
2006	Invited Lecture: Antidiabetic Effects of ARBs. International Seminar in Endocrinology, Medical Research Institute, Kitano Hospital, Kitano, Japan, March 23, 2006-03-20
2006	Invited Lecture: Mitochondrial Genomics and Therapeutics of the Metabolic Syndrome.Osaka University, Japan, March 24, 2006
2006	Invited Keynote Lecture: Mitochondrial Genomics and Therapeutics of the Metabolic Syndrome, Japanese Circulation Society, Nagoya, Japan, March 26, 2006
2006	Invited Lecture: Cardiometabolic ARBs with Anti-diabetic Effects Independent of Renin-Angiotensin System Blockade. Satellite Symposium of the Norwegian Society of Cardiology, Stavanger, Norway, April 27, 2006
2006	Plenary Lecture: New Opportunities for Treating Insulin Resistance, Hypertension, and the Metabolic Syndrome, Hong Kong College of Cardiology, Hong Kong, May 6, 2006
2006	Invited Lecture: Metabolic Syndrome or Not: Addressing Hypertension and Insulin Resistance, Satellite Meeting of the European Society of Hypertension, Madrid, Spain, June 14, 2006
2006	Invited Lecture: Metabolic Syndrome and Renin Angiotensin System Blockade: New Evidence, New Perspectives, 7th National Congress of Ambulatory Cardiology, Pisa, Italy, June 16, 2006

2006	Invited Lecture: New Opportunities for Treating Insulin Resistance, Hypertension, and the Metabolic Syndrome. Ho Chi Minh City, Vietnam, September 13, 2006
2006	Invited Lecture: New Opportunities for Treating Insulin Resistance, Hypertension, and the Metabolic Syndrome. Hanoi, Vietnam, September 15, 2006
2006	Invited Lecture. Treating Insulin Resistance in Patients with Hypertension. Taiwanese Society of Cardiology, Taipei, Taiwan, September 16, 2006
2006	Plenary Lecture: Pathogenesis and Treatment of the Metabolic Syndrome: Insights From the Mitochondrial Genome. The International Society of Hypertension, Fukuoka, Japan, October 17, 2006
2006	Invited Lecture: Mitochondrial Genomics and Therapeutics of the Metabolic Syndrome, Satellite Symposium of the International Society of Hypertension, Sapporo, Japan, October, 23, 2006
2006	Invited Lecture: New Opportunities for Preventing Diabetes in Patients with Hypertension. Saitama Medical University, Saitama, Japan, December 5, 2006
2007	Invited Lecture: Are the Anti-diabetic Effects of All ACE inhibitors and ARBs the Same? Satellite Symposium of the Belgian Society of Cardiology, Brussels, Belgium Feb 1, 2007
2007	Invited Lecture: New Opportunities for Preventing Diabetes and Cardiovascular Disease in Patients With Hypertension. Korean Society of Nephrology, Seoul, Korea, May 18, 2007
2007	Invited Lecture: New Treatment Strategies for Patients With Hypertension and Insulin Resistance. Clinical Workshop on Hypertension and Related Disease Management, Beijing, China, May 26, 2007
2007	Invited Lecture: New Opportunities for Preventing Diabetes in Patients with Hypertension and the Metabolic Syndrome. Nephrology Division, National University of Malaysia, June 7, 2007
2007	Invited Lecture: New Opportunities for Treating Insulin Resistance, Hypertension, and the Metabolic Syndrome, ASEAN CardioRenal Symposium, Kota Kinabalu, Malaysia, June 9, 2007

2007	Invited Lecture: New Opportunities for Treating Insulin Resistance, Hypertension, and the Metabolic Syndrome, Singapore Medical Society CME Symposium, Singapore, June 10, 2007
2007	Invited Lecture: Cardiovascular and Metabolic Effects of Angiotensin II Receptor Blockers: All Molecules Are Not the Same. International Symposium on Hypertension and the Metabolic Syndrome, Osaka, Japan, June 23, 2007
2007	Invited Lecture: New Opportunities for Preventing Diabetes and Cardiovascular Disease in Patients with Hypertension, 10th International Kitano Endocrinology Symposium, Osaka, Japan, June 25, 2007.?
2007	Invited Lecture: New Opportunities for Preventing Diabetes and Cardiovascular Disease in Patients with Hypertension, Division of Cardiology, Kagoshima University, Kagoshima, Japan, June 26, 2007
2007	Invited Lecture: Current Treatment Approaches and Remaining Needs in Cardiovascular Disease. International Symposium on Cardio & Vascular High-Risk Patients. Tokyo, Japan, July 16, 2007.
2007	Invited Lecture: Beyond the Classical ARB Profile. Department of Geriatric Medicine, Osaka University, Osaka, Japan, July 17, 2007
2007	Invited Lecture: New Perspectives on the Metabolic Syndrome. 8th Congress of the Umbria Regional Association of Ambulatory Cardiologists, Brufa di Torgiano, Italy, November 30, 2007
2007	Invited Lecture: Progress and Promise of Renin Angiotensin System Blockade. 10th Meeting on Geriatric Medicine, Osaka, Japan, December 8, 2007
2007	Invited Lecture: New Opportunities for Preventing Diabetes and Cardiovascular Disease in Patients with Hypertension. Department of Medicine, Kagawa University, Takamatsu, Japan, December 10, 2007
2007	Invited Lecture: Molecule Specific Effects of Angiotensin II Receptor Antagonists: Implications for Clinical Trials with Different ARBs. Sponsored Symposium on Cardiovascular Endocrinology, Kyoto, Japan, December 12, 2007
2008	Invited Lecture: Identification and Management of High Risk Patients: Focus on the Hypertension Metabolic Syndrome. International Symposium on Cardiovascular and Neurovascular Medicine, Hong Kong, February 24, 2008

2008	Invited Lecture: Cardiovascular Effects of ARBs: Are All Molecules the Same? Expert Forum on new Approaches in Cardio and Vascular Protection, Hong Kong, May, 20, 2008
2008	Invited Lecture: Angiotensin Receptor Blockers: Metabolic and Cardiovascular Effects of Angiotensin Receptor Blockers: Are All Molecules the Same? Joint International Symposium of the Journals of the American Society of Hypertension and Chinese Society of Hypertension, Dalian, China, May 22, 2008
2008	Invited Keynote Lecture: Nuclear and Mitochondrial Gene Variants that Influence the Hypertension Metabolic Syndrome: Satellite Symposium of the International Society of Hypertension on the Etiology of Genetic Hypertension and Metabolic Syndrome, Prague, Czech Republic, June 20, 2008
2008	Invited Speaker: Prevention of CV Disease in High Risk Patients, Osaka Symposium on Hypertension and Metabolic Syndrome, Osaka, Japan, June 28, 2008
2008	Keynote Lecture: Mechanisms of Hypertension and the Metabolic Syndrome: Lessons from the Spontaneously Hypertensive Rat. Japanese Society of Hypertension, Sapporo, Japan, October 10, 2008
2008	Invited Speaker: Reducing Metabolic and CV Risk in Patients with Hypertension and the Metabolic Syndrome, Kanazawa University, Kanazawa, Japan, Nov 17, 2008
2008	Invited Speaker: Cardioprotective and Antidiabetic Effects of Angiotensin Receptor Blockers: Fact vs Fiction, Kagoshima University, Kagoshima, Japan, Nov 18, 2008
2009	Invited Speaker: Preventing Diabetes and CV Disease with Antihypertensive Drugs: Current Options and Future Directions. Expert Meeting, Sapporo, Japan, May 19, 2009
2009	Invited Speaker: Beyond Blood Pressure Lowering: Which ARBs Prevent Diabetes and CV Disease in High Risk Patients? Asian-Pacific Cardiovascular Congress, Kyoto, Japan, May 22, 2009
2009	Program Chair: 3rd International Symposium on Hypertension and the Metabolic Syndrome, Osaka, Japan, June 6, 2009

2009	Invited Speaker: The Need for Greater Cardiovascular and Metabolic Protection Beyond Inhibition of the Renin Angiotensin System. 3rd International Symposium on Hypertension and the Metabolic Syndrome, Osaka, Japan, June 6, 2009
2009	Invited Speaker: Identifying New Opportunities for Prevention of Diabetes and CV Disease in Patients with Hypertension. Dept. of Medicine, Chiba University, Chiba, Japan, June 8, 2009
2009	Invited Speaker: Identification of Antihypertensive Agents That Prevent Diabetes and CV Disease in High Risk Patients. Dept. of Medicine, Hiroshima University, June 9, 2009
2009	Invited Speaker: Can Telmisartan Protect Against New Onset Diabetes? European Society of Cardiology Satellite Symposium, Barcelona, Spain, August 31, 2009
2009	Invited Speaker: Novel Mechanisms Regulating Blood Pressure Revealed By Genetic Studies of the Spontaneously Hypertensive Rat. Society for Hypertension Related Disease Model Research, Tokyo, Japan, September 4, 2009
2009	Invited Speaker: Preventing Diabetes and CV Disease in Patients with Hypertension:New Research and Treatment Opportunities. Department of Molecular Pathology, University of Yamanashi, Yamanashi, Japan, September 7, 2009
2009	Keynote Lecture: Is C-Reactive Protein a Marker of Mediator of Metabolic Syndrome, Diabetes, and Risk for Cardiovascular Disease?. Japanese College of Cardiology, Sapporo Japan, September 19, 2009
2009	Invited Lecture: Next Generation Angiotensin Receptor Blockers. Japanese College of Cardiology, Sapporo, Japan, September 19, 2009
2009	Invited Lecture: On the Cutting Edge: New Developments in Treatment of Hypertension and the Metabolic Syndrome. International Symposium on Cardiovascular and Life Style Related Disease, Tokyo, Japan, November 28, 2009
2009	Invited Lecture: Going Beyond Discovery of Genes for Complex Traits: Recent Lessons from Cd36. International Symposium on Rat Genomics and Models. Cold Spring Harbor Laboratory, December 2, 2009
2010	Invited Lecture: Choosing the Ideal Anti-Hypertensive Agent for CV Risk Management: Malaysian Society of Hypertension, Kuala Lumpur, Malaysia, January 29, 2010

2010	Invited Lecture: Next Generation Angiotensin Receptor Blockers. International Congress of Endocrinology, Kyoto, Japan, March 30, 2010
2010	Invited Lecture: Next Generation Angiotensin Receptor Blockers: New Opportunities for Preventing Vascular Injury and Renal Damage. International Society of Nephrology NEXUS Meeting Luncheon Symposium, Kyoto, Japan, April 16, 2010
2010	Invited Lecture: Next Generation ARBs. International Expert Meeting, Juntendo University, Tokyo, Japan, April 20, 2010
2010	Invited Lecture: Next Generation Angiotensin Receptor Blockers. International Expert Meeting, Keio University, Tokyo, Japan, April 21, 2010
2010	Invited Lecture: Molecular Genetics and Therapeutics of Hypertension and the Metabolic Syndrome: Lessons from the Spontaneously Hypertensive Rat. 4th Annual Symposium on Hypertension and the Metabolic Syndrome, Osaka, Japan, June 12, 2010
2010	Invited Lecture: Next Generation Multifunctional ARBs: Beyond the Renin-Angiotensin System. 6th International Conference on the Biology, Chemistry, and Therapeutic Applications of Nitric Oxide, Kyoto, Japan, June 16, 2010
2010	Invited Lecture: Protecting Against CV Events in High Risk Patients: Beyond the Renin-Angiotensin System. Japanese Society of Nephrology, Kobe, Japan, June 17, 2010
2010	Invited Lecture: International Okamoto Award Lecture of the Japan Vascular Disease Research Foundation. 14th International Symposium on the Spontaneously Hypertensive Rat, Montreal, Canada, September 23, 2010
2010	Invited Lecture: Next Generation Angiotensin Receptor Blockers. Division of Cardiovascular Medicine, Juntendo University, Tokyo, Japan, October 27, 2010
2010	Invited Lecture: Molecular Genetics and Therapeutics of the Metabolic Syndrome: Lessons from the Spontaneously Hypertensive Rat. 18th Annual Meeting of the Japanese Vascular Biology and Medicine Organization, Osaka, Japan, December 2, 2010
2011	Invited Lecture: Next Generation Multifunctional ARBs: Beyond the Renin Angiotensin System. International Expert Meeting, Okura Frontier Hotel, Tsukuba, Japan, June 23, 2011

2011	Invited Lecture: Genetic Dissection of the Hypertension Metabolic Syndrome. 5th Annual Hypertension and Metabolic Syndrome Symposium, Osaka, Japan, June 25, 2011
2011	Invited Lecture: Cardiovascular Protection: Pleiotropic Effects of Second Generation Angiotensin Receptor Blockers. Sponsored Symposium, XLIV Venezuela Congress of Cardiology, August 4, 2011
2011	Invited Lecture: Next Generation Angiotensin Receptor Blockers: Beyond the Renin Angiotensin System. Jichi Medical University, Tochigi, Japan, September 29, 2011
2011	Invited Lecture: Next Generation Angiotensin Receptor Blockers: Beyond the Renin-Angiotensin System, Expert Meeting with National Cerebral and Cardiovascular Center of Japan, Osaka, Japan, October 21, 2011
2011	Invited Lecture: Next Generation Angiotensin Receptor Blockers: Beyond the Renin Angiotensin System, Department of Nephrology and Hypertension, Shiga University of Medical Science, Otsu, Shiga, Japan, November 8, 2011
2011	Invited Lecture: Next Generation Angiotensin Receptor Blockers: Beyond the Renin Angiotensin System, Department of Cardiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan, November 30, 2011
2011	Invited Lecture: Genetic Dissection of the Metabolic Syndrome in Experimental Hypertension, Anti-Aging Society Symposium, Osaka, Japan, December 3, 2011
2012	Invited Lecture: What is the Optimal Drug for Hypertension Treatment? Fukushima Medical University, Fukushima, Japan, March 14, 2012
2012	Keynote Lecture: C-Reactive Protein, Inflammation, and the Metabolic Syndrome, 76th Annual Meeting of the Japanese Circulation Society, Fukuoka, Japan, March 17, 2012
2012	Invited Lecture: What is the Optimal Drug for Hypertension Treatment? Department of Cardiology, Aichi Medical University, Nagoya, Japan, April 12, 2012
2012	Invited Lecture: Angiotensin Receptor Blockers and Cardiovascular Protection. Medellín, Colombia, May 28, 2012
2012	Invited Lecture: The Mitochondrial Genome and Risk for the Metabolic Syndrome. 6th annual Meeting on the Hypertension and Metabolic Syndrome, Osaka, Japan, July 7, 2012

2012	Invited Lecture: What is the Optimal Drug for Hypertension Treatment. 4th Seminar of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University, Tokyo, Japan, November 15, 2012
2013	Invited Lecture: An Update on CV Protection With Antihypertensive Drugs: Surprising Results from Recent Clinical Trials. Department of Medicine, German Hospital of Santiago, Santiago, Chile, April 24, 2013
2013	Invited Lecture: A Major Revision of the Principal Unifying Theory of Hypertension. 7th Annual International Meeting on Hypertension and Metabolic Syndrome, Osaka, Japan, June 29, 2013
2013	Invited Lecture: A major revision of the principal unifying theory of salt-sensitive hypertension: New emphasis on a causal role for primary abnormalities in vascular resistance. Japanese Vascular Biology and Medicine Organization, Osaka, Japan, September 26, 2013
2014	Invited Lecture: Future Medicine: Beyond Gene Discovery. 14th Annual Meeting of the Japanese Society for Anti-Aging Medicine, Osaka, Japan, June 8, 2014
2014	Invited Lecture: Initiation of Hypertension by Salt or Obesity: What Are the Hemodynamic Mechanisms?" 8th Annual International Meeting on Hypertension and Metabolic Syndrome, Osaka, Japan, June 28, 2014
2014	Invited Lecture: Risks and Benefits of Antihypertensive Drugs That Block the Renin-Angiotensin System. Department of Medicine, University of Chile, Santiago, Chile, July 14, 2014
2014	Invited Lecture: Misconceptions About the Genetics and Renal Mechanisms of NaCl-Induced Hypertension. Laboratory of Integrative Physiology, Millennium Institute of Immunology and Immunotherapy and Chronic Kidney Disease Center, University of Chile, Santiago, July 15, 2014
2014	Invited Lecture: What is the Optimal Drug for Treatment of Hypertension? International Expert Meeting, Eastern Chiba Medical Center, Togane City, Japan, September 8, 2014
2014	Invited Lecture: What is the Optimal Drug for Treatment of Hypertension? International Expert Meeting, Asahi General Hospital, Asahi-city, Japan, September 10, 2014
2015	Invited Lecture: Understanding the Mechanisms of Salt-Sensitivity and Salt-Resistance. Hypertension and Metabolic Syndrome Symposium, Osaka, Japan, June 27, 2015

2015	Invited Lecture: The Vasodysfunction Theory of Salt-Sensitivity - Lessons from Animal Models. 51st Annual Meeting of the Society for Hypertension Related Disease Models Research. Osaka, Japan, October 30, 2015.
2016	Invited Lecture The Vasodysfunction Theory of Salt- Sensitivity. Department of Clinical Pathology and Clinical Laboratories., Tokyo University, Japan, March 4, 2016
2016	Invited Lecture: What Causes Resistance to Salt-Induced Hypertension ? 10th Annual Symposium on Hypertension and the Metabolic Syndrome, Osaka Japan, June 25, 2016
2016	Invited Lecture: A New Theory of Salt-Induced Hypertension: Implications for Clinical Management, International Expert Meeting, Hiroshima, Japan, June 30, 2016
2016	Invited Lecture: Mechanisms of Monogenic and Polygenic Forms of Salt-Sensitivity. Cardiovascular Genetics Satellite Meeting of the International Society of Hypertension and 17th Annual International SHR Symposium. Tokyo, Japan, September 22, 2016
2017	Invited Lecture: Mechanism-Based Functional Foods for the Prevention of Hypertension and Cardiovascular Disease. 65th Annual Meeting of the Japanese College of Cardiology, Osaka, Japan, September 30, 2017
2017	Invited Lecture: A New Unified Mechanism for Salt-Sensitive Hypertension. Japanese Society of Hypertension, Ehime, Japan, October 20, 2017
2017	Invited Lecture: How Does Salt Make the Blood Pressure Go Up? It's Not What You Have Been Told. Research Center for Advanced Science and Technology, Division of Clinical Epigenetics, Tokyo University, Japan, October 23, 2017
2017	Invited Lecture: A New Theory of Salt-Induced Hypertension: Implications for Clinical Management. National Congress of Cardiology, Mexican College of Cardiology, Guadalajara, Mexico, November 3, 2017
2019	Invited Lecture: New Strategies for Preventing Salt-Induced Hypertension. Japanese Society of Hypertension, Tokyo, Japan, October 25, 2019
2019	Invited Lecture: Functional Foods That Promote Salt Resistance and Reduce the Risk for Salt-Induced Hypertension. Japanese Society of Functional Foods. Tokyo, Japan, December 7, 2019

2020	Invited Lecture: Mechanism Based Strategies for Preventing Hypertension on a Global Scale. Japanese Society of Hypertension, Okinawa, Japan. October 23, 2020 (meeting canceled due to COVID-19)
2020	Invited Lecture: Dietary Nitrate for Prevention of Salt-Induced Hypertension. International Society of Hypertension Satellite Symposium, Glasgow, Scotland. May 28, 2020 (meeting canceled due to COVID-19)
2021	Invited Lecture: New Strategies to Prevent Salt-Induced Hypertension. International Society of Hypertension, 19th International SHR Symposium, April 11, 2021. Meeting held by Zoom remote due to COVID-19
2022	Invited Lecture: The Usual Cause of Salt-Induced Hypertension: Abnormally Increased Sodium Retention or Abnormally High Vascular Resistance? International Society of Hypertension, Kyoto, Japan, October 13, 2022
2022	Invited Lecture: Mechanism Based Strategies for Preventing Salt-Induced Hypertension: Lessons Learned from Animal Models. Cardiovascular Disease Model Satellite Meeting of the International Society of Hypertension, Kyoto, Japan, October 17, 2022
2022	Invited Lecture: How Does Salt Make the Blood Pressure Go Up? Department of Geriatric Medicine, Osaka University, Osaka, Japan, October 17, 2022
2023	Invited Lecture: New Findings on Salt-Dependent Hypertension: Implications for Prevention and Clinical Management. University of British Columbia, Vancouver, Canada, January 13, 2023.
2023	Invited Lecture: New Findings on Salt-Dependent Hypertension: Implications for Prevention and Clinical Management. Department of Medicine, Showa University School of Medicine, Tokyo, Japan, June 22, 2023
2023	Invited Lecture: New Findings on Salt-Dependent Hypertension: Implications for Prevention and Clinical Management. International University of Health and Welfare, School or Medicine Department of Medicine, Narita Chiba, Japan, June 23, 2023

# **INVITED PRESENTATIONS - NATIONAL**

2000	Conference Chair and Organizer, American Society of Hypertension- John Laragh Research Conference on Advances in Hypertension Research: Hypertension and the New Biology of Obesity, Boca Raton, Florida, January 13-15, 2000
2000	Invited Speaker: The Genome Project and Gene Expression Analysis in Hypertension Research: The Rat Genome. The American Heart Association Scientific Sessions, New Orleans, LA, November 12, 2000
2001	Chair and Organizer: New Frontiers in Aldosterone/Mineralocorticoid Biology: A Reemerging Force in Target Organ Damage and Hypertension. John H. Laragh Conference on Advances in Hypertension Research, American Society of Hypertension, Scottsdale, AZ, January 11-13, 2001
2001	Invited Speaker: Genetics of Hypertension. The American Society of Hypertension Clinical Review Course in Hypertension, Chicago, IL, March 24, 2001
2001	Invited Speaker: Use of Congenic Strains, Transgenic Strains, and cDNA Microarrays to Identify Hypertension Related QTLs at the Molecular Level. American Heart Association Workshop on Genetics and Genomics and Their Approaches to Understanding Mechanisms of Hypertension and Cardiovascular Disease, Chicago, IL Sept 22, 2001
2001	Invited Speaker: Genetics of Risk Factor Clustering in Experimental Hypertension. The American Society of Human Genetics - Session on the Genetics of Hypertension, 51st Meeting of the American Society of Human Genetics, San Diego, CA October 13, 2001
2002	Chair and Program Director: American Society of Hypertension 3rd Annual Laragh Conference on Advances in Hypertension Research: Target Organ Damage in Hypertension: Mechanisms, Prevention, and Management, Palm Beach, FL, January 31-February 2, 2002
2002	Invited Speaker: Using Congenic and Transgenic Strains to Understand the Molecular Pathophysiology of Syndrome X and Hypertension. The American Physiological Society, Experimental Biology Meetings 2002, New Orleans, LA, April 22, 2002
2002	Invited Chair: Gene Environment Interactions in Obesity. Physiology InFocus session of American Physiological Society, 2002, New Orleans, LA, April 21, 2002

2003	Invited Speaker: Genetics of Hypertension: Implications for Clinical Practice. American Society of Hypertension, Clinical Hypertension Course, New Orleans, LA, Feb 14, 2003
2003	Invited Speaker: Discovery of Novel ARBs That Specifically Target Insulin Resistance and the Dysmetabolic Syndrome. 18th Annual Scientific Meeting of the American Society of Hypertension, New York, New York, May 16, 2003
2003	Invited Speaker: The Metabolic Syndrome and Renal Disease: Molecular Mechanisms and Emerging Therapeutic Approaches. American Society of Nephrology Postgraduate Education Course, San Diego, CA, November 12, 2003
2003	Invited Speaker: Genetics, Hypertension, and the Kidney. American Society of Nephrology Postgraduate Education Course, San Diego, CA, November 12, 2003
2004	Invited Chair: Physiological Genomics in Hypertension and Cardiovascular Medicine. The American Society of Hypertension, New York, NY, May 20, 2004
2004	Invited Lecture: Molecular Genetics and Therapeutics of the Hypertension Metabolic Syndrome. Renal Week Symposium on Genetics, Race, and Cardiovascular/Renal Disease, the American Society of Nephrology, St. Louis, Missouri, October 30, 2004
2005	Invited Chair: Clues to the Etiology of Hypertension from Genetics to Genomics. The American Society of Hypertension, San Francisco, CA, May 16, 2005
2006	Novartis Award Lecture of the Council for High Blood Pressure Research of the American Heart Association. Molecular Genetics and Therapeutics of the Hypertension Metabolic Syndrome: Insights From Genetic Models, San Antonio, TX, Oct 6, 2006
2007	Invited Lecture: Potential Role of Renin Angiotensin System Blockade in Cardiometabolic Risk Management. National Education Summit of the Vascular Biology Working Group, Orlando, FL, November 16, 2007
2010	Invited Presentation: Genome Wide Association Studies in Unlocking the Genetic Basis of Human Hypertension: Strengths and Limitations, American Society of Hypertension, May 2010
2010	Invited Presention: Next Generation ARBs, Takeda Pharmaceuticals North America, Deerfield, IL, September 15, 2010

2011	Invited Presentation: Genetics of Experimental Hypertension: Translation to Humans, American Society of Hypertension, New York, New York, May 21, 2011
2011	Invited Presentation: Cd36 Expression as Genetic Determinant of Risk for Hypertension, American Society of Nephrology, Philadelphia, PA, November 12, 2011
2011	Invited Presentation: Next Generation Angiotensin Receptor Blockers, Takeda Pharmaceuticals North America, Chicago, Illinois, December 7, 2011
2012	Invited session chair and speaker: Unifying Theories of Hypertension, Workshop of the AHA Council for High Blood Pressure Research, Washington DC, September 19, 2012
2013	Invited Presentation: Genetic Determinants of the Risk for Hypertension and Metabolic Syndrome in the Spontaneously Hypertensive Rat. Heart and Kidney Institute, College of Pharmacy, University of Houston, Houston, Texas, April 3, 2013
2013	Invited Lecture: The Pathogenesis of NaCl-Induced Hypertension: How Did Genetics Lead us Astray? Cold Spring Harbor Laboratory International Meeting on Rat Genomics and Models, Cold Spring Harbor, New York, December 13, 2103
2014	Invited Lecture: How Does NaCl Make the Blood Pressure Go Up? Department of Physiology, Wayne State University School of Medicine, September 9, 2014
2014	Invited Lecture: How Does NaCl Make the Blood Pressure Go Up? It's Not What You've Been Told By Either the Renal Physiologists or Molecular Geneticists. Frontiers in Cardiovascular Science Seminar, University of Michigan Cardiovascular Center, Ann Arbor, Michigan, September 13, 2014
2017	Invited Lecture: How Does NaCl Make the Blood Pressure Go Up? It's Not What You've Been Told by Either the Renal Physiologists or Molecular Geneticists. Center for Hypertension Research and the Abboud Cardiovascular Research Center, University of Iowa College of Medicine, March 31, 2017
2017	Invited Lecture: How Does Salt Make the Blood Pressure Go Up? It's Not What You've Been Told. Center for Clinical and Translational Science, Rockefeller University, New York, September 27, 2017

2018 Invited Lecture: Surprising New Findings on Salt and

Hypertension. Medicine Grand Rounds, NCH Health Care

System, Naples, Florida, December 6, 2018.

#### **INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS**

2000 Invited Speaker: Genetic Dissection of Insulin Resistance, Dyslipidemia, and Hypertension using cDNA Microarrays, Congenic Strains, and Transgenic Strains. Department of Nutritional Science, University of California, Berkeley,

October 4, 2000

2000 Invited Speaker: Clustering of Insulin Resistance,

Dyslipidemia, and Hypertension: New Insights into Primary Mechanisms of Syndrome X. The Jackson Cardiovascular-Renal Meeting, The University of Mississippi, Jackson MS,

November 8-11, 2000

2001 Invited Speaker: Clustering of Insulin Resistance,

Dyslipidemia, and Hypertension: New Insights into Primary

Genetic Mechanisms of Experimental Syndrome X.

Endocrinology Grand Rounds, University of California, San

Francisco, February 14, 2001

2001 Invited Speaker: Genetic Determinants of Hypertension

Induced Renal Damage. The Southern Society of Clinical

Investigation, New Orleans, LA, March 1, 2001

2001 Invited Seminar: Genetics of Experimental Hypertension and

Target Organ Damage. Program in Vascular Biology, Department of Physiology, State University of New York,

Stony Brook, NY, April 26, 2001

2001 Invited Speaker: Genetics, Hypertension, and the Kidney,

Nephrology Grand Rounds, Stanford University Medical

Center, November 29, 2001

2002 Invited Speaker: Mechanisms of the Hypertension Metabolic

Syndrome X, Department of Medicine Grand Rounds, Loyola

University, Chicago, ILL, March 19, 2002

2002 Medical Staff Conference: Problems in Hypertension

Management. Kern Medical Center, Bakersfield, CA, Nov 7,

2002

2003 Invited Speaker: Identification of Angiotensin II Receptor

Antagonists With Selective PPAR gamma Modulating Activity. Pfizer Central Research, Ann Arbor, Michigan, December 9,

2003

2004	Invited Speaker: Beyond QTL Mapping: Identification of QTL at the Molecular Level. UCSF Program in Human Genetics, San Francisco, CA, January 12, 2004
2004	Invited Speaker: Identifying QTL at the Molecular Level by Genome Scanning of Congenic and Recombinant Inbred Strains. Vascular Biology Program, Department of Pathology, University of Washington, Seattle, WA, March 26, 2004
2004	Invited Speaker: The Influence of Rapp's Paradigm on the Field of Experimental Hypertension Research. International Cardiovascular Genomics Symposium, Medical College of Ohio, May 17, 2004
2004	Invited Lecture: Identification of New Treatment Strategies for Insulin Resistant Hypertension and the Metabolic Syndrome. Endocrinology Grand Rounds, Stanford University, October 20, 2004
2004	Invited Lecture: Treating Insulin Resistant Hypertension and the Metabolic Syndrome. Boehringer Ingelheim Co. Advisory Board, Toronto, Canada, November 27, 2004
2005	Invited Lecture: Identification of New Treatment Strategies for Insulin Resistance, Hypertension, and the Metabolic Syndrome. Georgetown University Nephrology
2006	Invited Lecture: Translational Genomics and Therapeutics of Hypertension and Type 2 Diabetes. Grand Rounds, UCSF Department of Laboratory Medicine, April 3, 2006
2007	Invited Panelist: Mentor-Mentee Relationships. Renal Research Seminar, Nephrology Division, University of California, San Francisco
2007	Invited Lecture: Pathogenesis and Treatment of the Metabolic Syndrome: New Insights from the Mitochondrial Genome. Department of Nutritional Sciences and Toxicology, University of California, Berkeley, CA, September 12, 2007
2008	Invited Lecture: Molecular Genetics and Therapeutics of the Hypertension Metabolic Syndrome: Insights from Genetic Models. Renal Grand Rounds, Department of Medicine, University of California, San Francisco, CA, April 23, 2008
2009	Invited Lecture: Searching for Novel Renal Mechanisms of Hypertension. Renal Grand Rounds, Department of Medicine, University of California, San Francisco, August 12, 2009
2010	Invited Lecture: Molecular Genetics and Therapeutics of the Metabolic Syndrome: Insights from Genetic Models, Department of Pathology and Laboratory Medicine, University of California, Irvine, January 8, 2010

2010	Leonard Share Memorial Lecture: E.E. Muirhead.Hypertension Research Day, University of Tennessee Health Science Center, Memphis, Tennessee, November 3, 2010
2012	Invited Lecture: Are You Using the Wrong Diuretic for Hypertension? Chlorthalidone vs. HCTZ. Renal Grand Rounds, Department of Medicine, University of California, San Francisco, September 5, 2012
2014	Invited Lecture: Genetics of Common and Rare Forms of Hypertension. Seminar in Human Genetics for the Integrative Genetics and Genomic Graduate Group, University of California, Davis, February 24, 2014
2014	Seminar: Genetics of Common and Rare Forms of Hypertension: Why the Lack of Mechanistic Insights? Institute of Human Genetics, University of California, San Francisco, March 3, 2014
2014	Invited Lecture: Misconceptions About the Genetics and Renal Mechanisms of NaCl-Induced Hypertension. Nephrology Grand Rounds, Department of Medicine, University of Calfornia, Davis, April 29, 2014
2020	Invited Lecture: Mineralocorticoid Hypertension. Endocrinology Fellows Teaching Conference. Department of Medicine, University of California, San Francisco, October 14, 2020
2021	Invited Lecture: Mineralocorticoid Hypertension. Endocrinology Fellows Teaching Conference. Department of Medicine, University of California, San Francisco, October 20, 2021
2021	Invited Lecture: Electrolytes and Hypertension. Continuing Education Program for Clinical Laboratory Scientists, UCSF Medical Center, San Francisco, CA, December 1, 2021
2023	Invited Lecture: Investigating Endocrine Results that Don't Make Sense. Endocrinology Grand Rounds, UCSF School of Medicine. February, 2023

# **CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT ACTIVITIES**

2010	American Society of Hypertension
2012	American Society of Hypertension
2013	American Society of Hypertension
2014	American Heart Association Council for High Blood Pressure Research

2017	American Heart Association Hypertension Council	
2021	International Society of Hypertension	
GOVERNMEN	T AND OTHER PROFESSIONAL SERVICE	
1995 - 1995	NIH Expert Panel on Genetic Models and Transgenic Resources for Hypertension	Committee Member
1995 - 1995	NIH Expert Panel on Genetic Strategies for Heart, Lung, and Blood Diseases	Committee Member
1996 - 1996	NIH Experimental Cardiovascular Sciences Study Section	Reviewer, ad hoc
1999 - 1999	NIH/NIDDK Review Panel on Diabetic and Non-Diabetic Susceptibility Genes	Committee Member
1999 - 1999	NIH Special Emphasis Panel on Minority Research Training	Committee Member
1999 - 1999	NIH Special Emphasis Panel on Experimental Cardiovascular Sciences	Committee Member
2000 - 2000	NIH Review Panel: SCOR Programs on Molecular Genetics of Hypertension	Committee Member
2004 - 2004	NIH/NHLBI Expert Panel on Future Directions in Hypertension Research	Committee Member
2005 - 2005	NIH/NHLBI Scientific Review Panel for Supplemental Applications to NIH Program in Genomic Applications	Committee Member
2007 - 2007	British Heart Foundation Research Programme Review	Committee Member
2009 - 2009	NIH/NHLBI Clinical and Integrative Cardiovascular Science Study Section	Reviewer, ad hoc
2009 - 2009	NIH/NHLBI RFA Challenge Grants Panel	Reviewer, ad hoc
2011 - 2012	Czech Science Foundation Review Panel	Committee Member
2012 - 2012	Max Delbruck Center for Molecular Medicine, External Review Panel	Committee Member
2102 - 2013	NIH Special Emphasis Panel Scientific Review Group, Genetics of Health and Disease Study Section	Committee Member
2015 - 2016	Czech Science Foundation, Scientific Review Panel	Grant Reviewer
2014 - 2016	Berlin Institute of Health, Berlin, Germany Scientific Grant Review Panel	Committee Member
2016 - 2016	NIH/NHLBI Program Project Review Study Section, Cardiovascular Systems Dynamics, Hypertension, and Hypertensive Disease	Grant Reviewer

2017 - 2017	Department of Pharmacology, University of Iowa College of Medicine, 5 Year Faculty Member Review	External Reviewer			
2017 - 2017	Czech Science Foundation and Grant Agency of the Czech Republic	Grant Reviewer			
2018 - 2018	Max Delbrück Center for Molecular Medicine, Scientific Advisory Board, Berlin, Germany	External Reviewer			
2019 - 2019	Rank and Tenure Committee, Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin	External Reviewer			
2020 - 2020	Promotion Review Committee, Monash University, Melbourne, Australia	External Reviewer			
2021 - 2021	Czech Science Foundation, Prague, Czech Republic	Invited Grant Reviewer			
UNIVERSIT	UNIVERSITY AND PUBLIC SERVICE				

**UC SYSTEM AND MULTI-CAMPUS SERVICE** 

# **UNIVERSITY SERVICE**

2002 - 2004	Executive Board, University Pathology Consortium	UCSF representative	
UCSF CAMPU	SWIDE		
1999 - 2000	Chest Pain Management Committee, UCSF-Stanford Health Care	UCSF representative	
2004 - 2005	Technical Liaison Committee, UCSF and Blood Systems Inc	Committee Member	
1999 - 2010	UCSF General Clinical Research Center Advisory Committee	Committee Member	
2016 - 2018	Lowering Our Costs Clinical Laboratories Utilization Team	Committee Member	
2014 - 2021	Clinical Laboratory Compliance Committee covering UCSF Moffitt-Long, Mission Bay, and Mt Zion Medical Centers	Committee Member	
2011 - present	Clinical Laboratory Quality Improvement Committees, UCSF Moffitt-Long and China Basin Laboratories	Committee Member	
SCHOOL OF	MEDICINE		
2003 - 2003	Ad hoc Promotion Committee, UCSF School of Medicine	Committee Member	

2003 - 2008	•	Committee Member
2004 - 2004	Ad hoc Promotion Committee, UCSF School of Medicine	Committee Chair
2000 - 2000	,	Committee Member
2002 - 2002		Committee Member
2010 - 2011	Faculty Search Committee for Director of Mass Spectrometry Clinical Laboratory, UCSF School of Medicine	Committee Chair
2011 - 2011	Stewardship Review Committee of the Department Chair of Laboratory Medicine	Interviewee
2012 - 2012	Stewardship Review Committee, The UCSF Center for Reproductive Sciences	Member
2017 - 2017	Five Year Review of Department Chair, UCSF Department of Laboratory Medicine	Interviewee
2021 - 2021	Faculty Meeting on Advancement and Promotion, UCSF School of Medicine Faculty Council	Panelist
DEPARTMENT	TAL SERVICE	
1999 - 1999	Chair's 5 year Review Committee, UCSF Dept. of Laboratory Medicine	Committee Member
1999 - 1999	Indirect Cost Recovery Committee, UCSF Dept. of Laboratory Medicine	Committee Member
1999 - 2001	Editorial Committee, Newsletter for the UCSF Dept. of Laboratory Medicine	Committee Member
2003 - 2003	Faculty Retreat Committee, UCSF Department of Laboratory Medicine	Committee Member
2005 - 2005	Ad Hoc Hiring Committee for Personnel Analyst, UCSF Dept of Laboratory Medicine	Committee Member
1999 - 2013	Chair's Advisory Committee, UCSF Department of Laboratory Medicine	Committee Member
2006 - 2013	CME Grand Rounds Planning Committee, UCSF Department of Laboratory Medicine	Committee Member
2014 - 2015	Departmental Advisory Committee (DAC) on compensation, UCSF Dept of Laboratory Medicine	Member
2006 - 2017	Planning Committee for Kabra and Brecher Lectures, UCSF Department of Laboratory Medicine	Committee Member

2019 - 2020	Departmental Advisory Committee (DAC) on Compensation UCSF Department of Laboratory Medicine	n, Commitee Member	
1999 - 2020	999 - 2020 Residency Training/Selection Committee, UCSF Department of Laboratory Medicine		
2020 - 2020	Resident Orientation, Faculty Q&A Panel, UCSF Department of Laboratory of Medicine	Faculty Panelist	
1999 - 2020	1999 - 2020 Committee on Appointments, Promotions, and Merit, UCSF Dept of Laboratory Medicine		
2006 - present Committee on Animal Research, UCSF Department of Laboratory Medicine		Committee Member	
COMMUNITY	AND PUBLIC SERVICE		
2011 - 2011	Summer Search San Francisco (summer opportunity program for low income youth)	Donor/Supporter	
2014 - 2016	Development School for Youth: All Stars Project of the Bay Area. Organizer and presenter of STEM workshops for high school students	/olunteer Speaker	
2012 - present	All Stars Project of the Bay Area: Benefit Luncheon Volunteer Program Member (non-profit organization providing performance-based development opportunities to youth throughout the Bay Area's poorest neighborhoods)		

# **TEACHING AND MENTORING**

2002 - present Type of teaching: Grand Rounds, Workshops, CME Courses, Sponsored Symposia, Department Seminars, Laboratory Medicine Core Course Lectures, One on One Teaching of Residents and Research Students and Fellows

#### **FORMAL TEACHING**

Academic Yr	Course No. & Title	Teaching Contribution	School	Class
		9 3 3 3 3 3 3 3		Size
2000 -	Core Curriculum,	Lectures in Clinical	Medicine	6
present	UCSF Laboratory	Chemistry		
	Medicine Residency			
	Program			

#### **INFORMAL TEACHING**

- 2002 2020 Teaching of lab students and fellows experimental hypertension research (100 hrs/yr)
- 2002 present Supervision and teaching of Laboratory Medicine Residents in Clinical Chemistry (100 hrs/yr)

# **MENTORING SUMMARY**

# PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

Dates	Name	Program or School	Mentor Type	Role	Current Position
2001 - 2002	Eugene Wong	UCLA undergraduat e		Mentored summer research	
2001 - 2001	Brendan Innes	Melbourne University	Research/Schola rly Mentor	PhD thesis advisor	
2002 - 2002	Celia Wang	Harvard Univ undergrad	Research/Schola rly Mentor	Mentored summer research	
2003 - 2003	Daniella Kim	UCSF medical student	Project Mentor	MD with thesis advisor	
2003 - 2004	Christopher Ho	CA State Univ undergrad	Research/Schola rly Mentor,Project Mentor	Mentored master's research	
2004 - 2004	Adam Benjafield	Sydney University	Project Mentor	PhD thesis advisor	
2004 - 2005	Derrick Chan	UCLA undergraduat e	Research/Schola rly Mentor,Project Mentor	Mentored summer research	
2004 - 2005	M. LaFemina	UCSF med student	Research/Schola rly Mentor,Project Mentor	Thesis adviser	
2005 - 2005	Yoichi Takeuchi	Sendai Univ. med student	Research/Schola rly Mentor,Project Mentor	Mentored summer research	
2009 - 2012	Ryan Vilardi	CSU masters student	Research/Schola rly Mentor,Project Mentor	Research laboratory advisor	
2011 - 2011	Berk Norman	High school student	Research/Schola rly Mentor,Project Mentor	Mentored summer research	

Dates	Name	Program or School	Mentor Type	Role	Current Position
2017 - 2018		student, Charles	Research/Schola rly Mentor,Project Mentor	Research co-supervisor	
2018 - 2018		student, Charles	Research/Schola rly Mentor,Project Mentor	Research co-supervisor	

# POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2001 - 2002	Nathan Qi, MD, PhD		Research/Schola rly Mentor,Project Mentor,Career Mentor	Research supervision	
2002 - 2003	Petr Mlejnek, PhD	UCSF postdoc	Research/Schola rly Mentor,Project Mentor	Research supervision	
2004 - 2006	Ken Sugimoto, PhD	UCSF postdoc	Research/Schola rly Mentor,Project Mentor,Career Mentor	Research supervision	
2005 - 2007	M Hyakukoku, MD,PhD	UCSF postdoc	Research/Schola rly Mentor,Project Mentor	Research supervision	
2006 - 2008		UCSF postdoc	Research/Schola rly Mentor,Project Mentor,Career Mentor	Research supervision	

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2009 - 2011	Takashi Kajiya, MD	UCSF postdoc	Research/Schola rly Mentor,Project Mentor,Career Mentor	Research supervision	
2011 - 2011	Christopher Liverman, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2011 - 2011	MIchael Bonham, MD, PhD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2011 - 2011	Tab Toochinda, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2012 - 2012	Taylor Sittler, MD, PhD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2012 - 2012	Cyril Jacquot, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2012 - 2012	Benjamin Buelow, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2012 - 2012	Yuna Kang, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2012 - 2012	Jessica Davis, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2013 - 2013	MIke Lindsey,MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2013 - 2013	Patty Goldhoff, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2013 - 2013	Kathleen Yang, MD	UCSF fellow, gynecologic oncology	Project Mentor	Thesis advice	

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2013 - 2013	Tara Saunders, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2013 - 2013	Jonathan Esensten, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2014 - 2014	Christy Perez- Valles, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2014 - 2014	Jamal Benhamida, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2014 - 2014	Jonee Taylor, MD	UCSF resident	Co- Mentor/Clinical Mentor	Advice on lecture preparation/presentation	
2014 - 2014	Joshua Menke, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2014 - 2014	Carey Eberle, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2015 - 2015	Zhen Yan, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2015 - 2015	Michele Moh, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2015 - 2015	Jessica Farrell, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2015 - 2015	Alexander Thurman, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2015 - 2015	Anna Plourde, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2015 - 2015	Wei Gu, MD, PhD	UCSF resident	Career Mentor,Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2016 - 2016	Boris Getman, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2016 - 2016	Nicole Therrien, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2016 - 2016	Jeanette Ruiz, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2016 - 2016	Nancy Greenland, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2016 - 2016	Arash Eslami, MD	UCSF resident	Career Mentor,Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2016 - 2016	Dianna Ng, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2017 - 2017	Emily Waterhouse, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2017 - 2017	Daniel Graham, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2017 - 2017	Joshua Anderson, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2017 - 2017	Jacob Spector, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2017 - 2017	Dana Balitzer, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2018 - 2018	Nicholas Ladwig, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2018 - 2018	Jeffrey Whitman, MD	UCSF resident	Career Mentor,Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2018 - 2019	Filip Jezek, PhD	Postdoctoral student Dept of Pathophysiol ogy, Charles University, Prague	Research/Schola rly Mentor,Career Mentor	Research co-supervisor	
2018 - 2018	Kent Truong, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2018 - 2018	Brian Shy, MD, PhD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2018 - 2018	Daniel Martig, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2018 - 2018	,	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2019 - 2019	Karen Zeigler, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2019 - 2019	Emilio Ramos, MD, PhD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2019 - 2019	Sagar Bapat, MD, PhD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2019 - 2019	Greg Goldof, MD, PhD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2019 - 2019	Daiva Mattis, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2019 - 2019	Andrew Levine, MD, PhD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2020 - 2020	Lauren Eversmeyer, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2020 - 2020	Hannah Lee, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2020 - 2020	Joanna Balcerek, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2020 - 2020	Nicole Croom, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2021 - 2021	Marietya Law, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2021 - 2021	Katie Sheahon, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2021 - 2021	Jordan Taylor, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2021 - 2021	Erron Titus, MD, PhD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2021 - 2022	Mimansa Geere, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2022 - 2022	Tyler Jankowski, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2022 - 2022	Brent Molden, MD	UCSF resident	Co- Mentor/Clinical Mentor	Clinical rotation supervisor	
2021 - 2022	Arvisais-Anhalt,	UCSF clinical informatics fellow		Clinical service supervisor	

# **FACULTY MENTORING**

Dates	Name	Position while Mentored	Mentor Type	Mentoring Role	Current Position
2001 - 2002	Jeff Chan, MD, PhD	Adjunct ProfessorUC SF	Research/Schola rly Mentor	Career advice	
2001 - 2002	Elizabeth St. Lezin, MD	Assistant ProfessorUC SF	Research/Schola rly Mentor,Career Mentor	Career advice	
2002 - 2004	R. DiNicolantonio, PhD	LecturerMelb ourne University	Research/Schola rly Mentor	Review of grant applications	
2001 - 2006	Michal Pravenec, PhD	Visiting ProfessorUC SF	Research/Schola rly Mentor	Research collaborator and advisor	
2004 - 2013	Jeff Chan, MD, PhD	Asst/Assoc Professor UC Irvine	Career Mentor	Career advice	
2005 - 2005	Deanna Kroetz, PhD	Assoc. ProfessorUC SF	Project Mentor	Review of grant application	
2006 - 2008	Nathan Qi, MD, PhD		Research/Schola rly Mentor,Project Mentor	Grant and research advice	
2009 - 2009	Kazutoshi Miyashita, MD	Assistant Professor,Kei o University	Research/Schola rly Mentor,Project Mentor	Research advice	

Dates	Name	Position while Mentored	Mentor Type	Mentoring Role	Current Position
2011 - 2014	Mark Seielstad, PhD	Associate Professor, UCSF	Career Mentor	Career and promotion advice	
2007 - 2020	MD	Assistant Professor,Os aka University	Research/Schola rly Mentor,Career Mentor	Research advice	
2008 - 2020	Koichi Yamamoto, MD	Assistant Professor,Os aka University	Research/Schola rly Mentor,Career Mentor	Research and career advice	
2012 - 2022	Deborah French, PhD	Associate Professor, UCSF	Career Mentor,Co- Mentor/Clinical Mentor	Career advice and support	
2022 - present		Assistant Professor, UCSF	Career Mentor,Co- Mentor/Clinical Mentor	Career advice and support	

# **VISITING FACULTY MENTORED**

1999 - 2000	Allyn Mark, MD, Professor of Medicine	University of Iowa College of Medicine
2000 - 2008	Michal Pravenec, PhD	Charles University and Czech Academy of Sciences

# **RESEARCH AND CREATIVE ACTIVITIES**

# **RESEARCH AND CREATIVE ACTIVITIES SUMMARY**

#### **RESEARCH AWARDS - Current**

Praemium Academiae     Award	International Coinvestigator	Donated 10 % effort	Pravenec (PI)
Academy of Sciences of th	1/1/2016	12/31/2023	
Molecular-based hemodyn dependent hypertension	amic mechanisms of salt-	\$ 250,000 direct/yr 1	\$ 1,250,000 total

Molecular, physiologic, and computer modeling studies of the hemodynamic mechanisms of experimental forms of salt-dependent hypertension

Contributor to experimental designs, data analysis, and computer modeling studies, and manuscript writing

# **RESEARCH AWARDS - PAST**

1. A126012	Principal Investigator	5 % effort	Kurtz (PI)
Sanofi Pharmaceuticals		7/31/2014	6/30/2016
Electrophoresis Study of SAR650984 and Anti-SAR		\$ 15,000 direct/yr	\$ 45,000 total
Antibody		1	

Capillary and immunofixation electrophoresis analysis of a novel therapeutic monoclonal antibody

Design, supervision, and analysis of the experiments

2. RO1 HL56028 Kurtz PI

NIH/NHLBI 01/01/1996 12/31/2013

New Experimental Models of Hypertension \$ 250,000 direct/yr \$ 4,250,000 total

1

3. PO1 HL35018 Kurtz unit

Ы

NIH/NHLBI 04/30/2003 05/01/2008

Unit: Genetics of Risk Factor Clustering in \$ 250, 000 \$ 1,250,000 total

Hypertension direct/yr 1

4. RO1 HL63709 Kurtz PI

NIH/NHLBI 09/01/2000 08/31/2005

Why do Metabolic Risk Factors Cluster in \$250,000 direct/yr \$1,250,000 total

Hypertension

5. RO1 HL56608 Kurtz PI

NIH/NHLBI 08/01/2000 07/31/2005

Kidney Specific Gene Transfer in Hypertension \$ 250,000 direct/yr \$ 1,250,000 total

1

#### PEER REVIEWED PUBLICATIONS

- 1. Hsu CH, Kurtz TW, Easterling RE, Weller JM: Potentiation of gentamicin nephrotoxicity by metabolic acidosis. Proc Soc Exper Biol Med. 146: 894-897, 1974.
- 2. Hsu CH, Kurtz TW, Preuss HG, Weller JM: Measurement of renal blood flow in the rat. Proc Soc Exper Biol Med 149:470-472, 1975.
- 3. Hsu CH, Kurtz TW, Goldstein JR, Keinath RD, Weller JM: Intrarenal hemodynamics in acute myohemoglobinuric renal failure. Nephron 17:65-72, 1976.
- 4. Hsu CH, Kurtz TW, Weller JM: The role of tubular necrosis in the pathophysiology of acute renal failure. Nephron 17:204-214, 1976.
- 5. Kurtz TW, Maletz RM, Hsu CH: Renal cortical blood flow in glycerol-induced acute renal failure in the rat. Circ Res 38:30-35, 1976.
- 6. Hsu CH, Kurtz TW: Effects of sodium intake on renal cortical blood flow distribution. Proc Soc Exper Biol Med 151:475-477, 1976.
- 7. Hsu CH, Kurtz TW, Waldinger TP: Cardiac output and renal blood flow in glycerol induced acute renal failure in the rat. Circ Res 40:178-182, 1977.
- 8. Hsu CH, Kurtz TW, Rosenzweig J, Weller JM: Renal hemodynamics in HgC12 induced acute renal failure. Nephron 18:326-332, 1977.
- 9. Hsu CH, Kurtz TW, Rosenzweig J, Weller JM: Intrarenal hemodynamics and ureteral pressure during ureteral obstruction. Investigative Urology 14:442-445, 1977.
- 10. Hsu CH, Kurtz TW, Weller JM: In vitro uptake of gentamicin by rat renal cortical tissue. Antimicrobial Agents Chemotherapy 12:192-194, 1977.
- 11. Hsu CH, Maletz RM, Rozas W, Kurtz TW: Renal tubular sodium and water excretion in antibiotic induced nephrotoxicity. Nephron 20:227-234, 1978.
- 12. Hsu CH, Kurtz TW, Rosenzweig J, Weller JM: Intrarenal hemodynamics and renal function in post-obstructive uropathy. Investigative Urology 15:348-351, 1978.
- 13. Kurtz TW, Hsu CH: Systemic hemodynamics in HgC12 induced acute renal failure. Nephron 21:100-106, 1978.
- 14. Hsu CH, Kurtz TW, Massari PU: Familial Azotemia: Impairment of renal urea excretion. N Engl J Med 298:117-121, 1978.
- 15. Kurtz TW, Hsu CH: Impaired distal nephron acidification in chronically phosphate depleted rats. Pfluegers Arch 377:229-234, 1978.
- 16. Kurtz TW, Hsu CH: Resolution of chylothorax after positive end- expiratory pressure ventilation. Arch Surg 115:73-74, 1980.
- 17. Hsu CH, Kurtz TW, Sands CE: Intrarenal vascular resistance in glycerol induced acute renal failure. Circ Res 45:583-587. 1980.
- 18. Hsu CH, Kurtz TW, Slavicek J: Effects of exogenous angiotensin II on renal hemodynamics in the awake rat. Circ Res 46:646-650, 1980.
- 19. Hsu CH, Kurtz TW: Renal hemodynamics in experimental acute renal failure. Nephron 27:204-208, 1981.

- 20. Hsu CH, Slavicek JM, Kurtz TW: Segmental renal vascular resistance in the spontaneously hypertensive rat. Am J Physiol 242:H961-H966, 1982.
- 21. Kurtz TW, Slavicek JM, Hsu CH: Blood viscosity in experimental acute renal failure. Nephron 30:348-351, 1982.
- 22. Kurtz TW, Morris RC Jr: Dietary chloride as a determinant of "sodium-dependent" hypertension. Science 222:1139-1141, 1983.
- 23. Kurtz TW, Morris RC Jr: Dietary chloride and bicarbonate as determinants of desoxycorticosterone hypertension. J Hypertension 2:371-373, 1984.
- 24. Kurtz TW, Morris RC Jr: Dietary chloride as a determinant of disordered Ca metabolism in salt?dependent hypertension. Life Sci 36:921-929, 1985
- 25. Kurtz TW, Morris RC: "Hypertension" in the Dahl salt-sensitive rat despite a diet deficient in sodium chloride. Science 230:808-810, 1985
- 26. Kurtz TW, Kabra PM, Booth BE, et. al.: Liquid chromatographic measurements of inosine, hypoxanthine, and xanthine in the study of fructose-induced degradation of adenine nucleotides in man and in the rat. Clin Chem 32:782-786, 1986
- 27. Kurtz TW, Hsu CH: Effects of furosemide diuresis on mercuric chloride induced acute renal failure in the rat. Nephron 43:279-282, 1986
- 28. Kurtz TW, Portale AA, Morris RC: Evidence of a difference in vitamin D metabolism between Spontaneously Hypertensive rats and Wistar-Kyoto rats. Hypertension 8:1015-1020, 1986
- 29. Kurtz TW, Morris RC: Attenuation of deoxycorticosterone hypertension by supplemental dietary calcium. J Hypertension 4:S129-S131, 1986
- 30. Kurtz TW, Morris RC: Biological Variability in Wistar-Kyoto Rats: Implications for research with the Spontaneously Hypertensive Rat. Hypertension 10:127-131, 1987
- 31. Kurtz TW, Al-Bander HA, Morris RC: Salt-sensitive essential hypertension in man: Is the sodium ion alone important? New Engl J Med 317:1043-1048, 1987
- 32. Karczmar GS, Kurtz TW, Tavares NJ, Weiner MW. Regulation of hepatic inorganic phosphate and ATP in response to fructose loading: An in vivo 31P NMR study. Biochimica Biophysica Acta, 1012:121-7, 1989.
- 33. Kurtz TW, Morris RC, Pershadshingh HA: The Zucker Fatty rat as a genetic model of obesity and hypertension. Hypertension 13:896-901, 1989.
- 34. Kurtz TW, Montano M, Chan L, Kabra P: Molecular evidence of genetic variability in Wistar? Kyoto rats: Implications for research with the Spontaneously Hypertensive Rat. Hypertension 13:188-192, 1989.
- 35. Kurtz TW, Simonet L, Kabra P, Wolfe S, Chan L, Hjelle B. Cosegregation of the renin allele of the spontaneously hypertensive rat with an increase in blood pressure. J Clin Invest 85:1328-1332, 1990.
- 36. Kurtz TW, Morris RC. Sodium-calcium interactions and salt-sensitive hypertension, American Journal of Hypertension 3:152s-155s, 1990.
- 37. Mockli G, Kabra P, Kurtz TW. Laboratory monitoring of cyclosporine levels. J Amer Acad Derm, 23:1275-1279, 1990.

- 38. Kurtz TW, Casto R, Simonet L, Printz M. Biometric genetic analysis of blood pressure in the spontaneously hypertensive rat. Hypertension 16:718-724, 1990.
- 39. Pravenec M, Kren V, Bila V, Kabra P, Krsiakova M, Simonet L, Kurtz TW. HXB and BXH sets of recombinant inbred strains: Strain distribution patterns of some genetic markers. Trans Proc, 22:2557-2558 1990.
- 40. Pravenec M, Kabra P, Kren V, Simonet L, Kurtz TW. Linkage between renin and fumarate hydratase genes in the rat. Trans Proc, 22:2555-2556, 1990.
- 41. Moulinier L, Venet T, Schiller NB, Kurtz TW, Morris RC, Sebastian A. Measurement of aortic blood flow by Doppler echocardiography: Day-to-day variability in normal subjects and applicability to clinical research. J Am Coll Card, 17:1326-1333, 1991.
- 42. Pravenec M, Kren V, Kunes J, Scicli AG, Carretero O, Simonet L, Kurtz TW. Cosegregation of blood pressure with an RFLP in the kallikrein gene family. Hypertension, 17:242-246, 1991.
- 43. Pravenec M, Simonet L, Kren V, Kunes J, Levan G, Szpierer J, Szpirer C, Kurtz TW. The rat renin gene: Assignment to chromosome 13 and linkage to the regulation of blood pressure. Genomics, 9:466-472, 1991.
- 44. Simonet L, St.Lezin E, Kurtz TW. Sequence analysis of the al Na+,K+-ATPase gene in the Dahl salt-sensitive rat. Hypertension 18:689-693, 1991.
- 45. Pravenec M, Simonet L, St.Lezin E, Kurtz TW. Assignment of rat linkage group V to chromosome 19 by single-strand conformation polymorphism analysis of somatic cell hybrids. Genomics, 12:350-356,1992.
- 46. St. Lezin E, Simonet L, Pravenec M, Kurtz TW. Hypertensive strains and normotensive "control" strains: How closely are they related? Hypertension, 19:419-424, 1992.
- 47. Kurtz TW, St. Lezin EM. Gene mapping in experimental hypertension. Journal of the American Society of Nephrology, 3:28-34, 1992.
- 48. Fenoy FJ, St.Lezin E, Kurtz TW, Roman RJ. Genetic heterogeneity and differences in glomerular hemodynamics between inbred colonies of Munich-Wistar rats. Journal of the American Society of Nephrology, 3:61-63, 1992
- 49. Iwai N, **Kurtz TW**, Inagami T. Further evidence of the SA gene as a candidate gene contributing to the hypertension in the spontaneously hypertensive rat. <u>Biochem Biophys</u> Res Commun, 188:64-69, 1992
- 50. Sudhir K, Kurtz TW, Yock PG, Connolly AJ, Morris RC. Potassium preserves endothelial function and enhances aortic compliance in Dahl rats. Hypertension 22:315-322, 1993
- 51. St. Lezin, EM, Pravenec M, Kurtz TW. New genetic models for hypertension research. Trends in Cardiovascular Medicine, 3:119-123, 1993.
- 52. Kurtz TW and Spence MA. Genetics of essential hypertension. American Journal of Medicine, 94:77-84, 1993.
- 53. St. Lezin EM, Kurtz TW. The renin gene and hypertension. Seminars in Nephrology, 13:581-585, 1993

- 54. Pershadsingh HA, Benson S, Szollosi J, Hyun, WC, Feuerstein BG, Kurtz TW. Effects of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension, 21:1020-1023, 1993.
- 55. Simon-Chazottes D, Wu H, Parmer RJ, Rozansky DJ, Szpirer J, Levan G, Kurtz TW, Szpirer C, Guenet JL, O'Connor DT. Assignment of the chromogranin A locus to homologous regions on mouse chromosome 12 and rat chromosome 6. Genomics, 17:252-255, 1993.
- 56. Kren V, Pravenec M, Bila V, Svobodova D, St.Lezin, Kurtz TW: Linkage between the RT8 alloantigen and interleukin 6 loci on rat chromosome 4. Transplantation Proceedings 25:2777, 1993.
- 57. Cicila GT, Rapp JP, Wang JM, St.Lezin EM, Ng, SC, Kurtz TW. Linkage of 11β hydroxylase mutations with altered steroid biosynthesis and blood pressure in the Dahl rat. Nature Genetics, 3:346-353, 1993.
- 58. Pravenec M, St.Lezin EM, Kren V, Wang J-M, Kurtz TW. Linkage mapping of alkaline phosphatase, a inhibin subunit, and g crystallin 1 on rat chromosome 9 and Na+,K+-ATPase α2 subunit, renin, and leukocyte common antigen on rat chromosome 13. Genomics, 19:190-191,1994.
- 59. Cicila GT, Rapp JP, Bloch KD, Kurtz TW, Pravenec M, Kren V, Hong CC, Quertermous T, Ng SC. Cosegregation of the endothelin-3 locus with blood pressure and relative heart weight in inbred Dahl rats. J Hypertension, 6:643-651, 1994.
- 60. Duru K, Farrow S, Wang J-M, Lockette W, Kurtz TW. The frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African-Americans with hypertension. American Journal of Hypertension, 7:759-762, 1994.
- 61. St. Lezin EM, Pravenec M, Wong A, Wang J-M, Merriouns T, Newton S, Stec DE, Roman RJ, Lau D, Morris RC, Kurtz TW. Genetic contamination of Dahl SS/Jr rats: Impact on studies of salt-sensitive hypertension. Hypertension, 23:786-790, 1994.
- 62. Kurtz TW. Genetic models of hypertension. Lancet 344:167-168, 1994.
- 63. Jacob, H., Brown, D., Bunker, R., Daly, M., Dzau, V., Goodman, A., Koike, G., Kren, V., Kurtz, TW., Lernmark, A., Levan, G., Mao, Y., Pettersson, A., Pravenec, M., Simon, J., Szpirer, C., Szpirer, J., Trolliet, M., Winer, E., and Lander, E. A genetic linkage map of the laboratory rat. Nature Genetics 9(1):63-69, 1995.
- 64. Pravenec M, Gauguier D, Schott JJ, Buard J, Kren V, Bila V, Szpirer C, Szpirer J, Wang JM, Huang H, St. Lezin E, Spence MA, Flodman P, Printz M, Lathrop GM, Vergnaud G, Kurtz TW. Mapping of Quantitative Trait Loci for Blood Pressure and Cardiac Mass in the Rat by Genome Scanning of Recombinant Inbred Strains, Journal of Clinical Investigation. 96:1973-1978. 1995.
- 65. Cover CM, Wang JM, St. Lezin EM, Kurtz TW, Mellon S. Molecular variants in the p450c11as gene as determinants of aldosterone synthase activity in the Dahl rat model of hypertension. Journal of Biological Chemistry, 270:16555-16560, 1995.
- 66. Huang H, Pravenec M, Wang J, Kren V, St.Lezin EM, Szpirer C, Szpirer J, Kurtz TW. Mapping and sequence analysis of the gene encoding the beta subunit of the epithelial sodium channel in experimental models of hypertension. J Hypertension 13:1247-1251, 1995.

67. St.Lezin EM, Pravenec M, Wong AL, Liu W, Wang N, Lu S, Jacob HJ, Roman RJ, Stec DE, Wang J, Reid IA, Kurtz TW. Effects of renin gene transfer on blood pressure and renin gene expression in a congenic strain of Dahl salt-resistant rats. Journal of Clinical Investigation 97:522-527, 1996.

- 68. Pravenec M, Gauguier D, Schott JJ, Buard J, Kren V, Bila V, Szpirer C, Szpirer J, Wang JM, Huang H, St. Lezin E, Spence MA, Flodman P, Printz M, Lathrop GM, Vergnaud G, Kurtz TW. A genetic linkage map in the rat derived from recombinant inbred strains. Mammalian Genome 7:117-127, 1996.
- 69. Bottger A, van Lith HA, Kren V, Krenova D, Bila V, Vorlicek J, Zidek V, Musilova A, Zbodinska M, Wang JM, van Zutphen LFM, Kurtz TW, Pravenec M. Quantitative trait loci influencing cholesterol and phospholipid phenotypes map to chromosome regions that contain genes regulating blood pressure in the spontaneously hypertensive rat. Journal of Clinical Investigation 98:856-862, 1996.
- 70. Pravenec M, Kren V, Wang JM, Bottger A, van Zutphen LFM, Kurtz TW. Linkage mapping of the carboxyl ester lipase gene (Cel) to rat chromosome 3. Mammalian Genome, 7: 559-660, 1996.
- 71. Otsen M, Den Bieman M, Kuiper MTR, Pravenec M, Kren V, Kurtz TW, Jacob HJ, Lankhorst AE, Van Zutphen BFM. Use of AFLP markers for gene mapping and QTL detection in the rat. Genomics 37:289-294, 1996.
- 72. Pravenec M, Kren V, Wang JM, Kurtz TW. Linkage mapping of the cellular retinoic acid binding protein 1 (Crabp1) to rat chromosome 8. Mammalian Genome 8:455-456, 1997.
- 73. Kren V, Pravenec M, Moisan M-P, Courvoisier H, Krenova D, Szpirer C, Szpirer J, Stahl F, Wang JM, St. Lezin EM, Kurtz TW. Report on rat chromosome 8. Rat Genome 3: 76-97, 1997.
- 74. Wang JM, Pravenec M, Kren V, Kurtz, TW. Linkage mapping of the Na-K-2Cl cotransporter gene (Slc12a1) to rat chromosome 3. Mammalian Genome, 8:379-379, 1997.
- 75. Kren V, Kurtz, TW, Krenova D, Bila, V, Printz M, Pravenec M. Rat genome mapping using recombinant inbred strains. Transplantation Proceedings, 29: 1768-1768, 1997.
- 76. Krenova D, Kurtz TW, Wang JM, Pravenec M, Kren V. Map of the differential segment of rat chromosome 8 in the SHR-Lx congenic strain. Transplantation Proceedings, 29: 1769-1769, 1997.
- 77. Cicila GT, Dukhanina OK, Kurtz TW, Walder R, Garrett MR, Dene H, Rapp JP. Blood pressure and survival of a chromosome 7 congenic strain bred from Dahl rats. Mammalian Genome 8:896-902, 1997.
- 78. Morikang E, Benson SC, Kurtz TW, Pershadsingh HA. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. American Journal of Hypertension, 10:440-446, 1997.
- 79. Kren V, Pravenec M, Lu S, Krenova D, Wang JM, Wang N, Merriouns T, Wong A, St. Lezin E, Lau D, Szpirer C, Szpirer J, Kurtz TW. Genetic isolation of a region of chromosome 8 that exerts major effects on blood pressure and cardiac mass in the spontaneously hypertensive rat. Journal of Clinical Investigation 99:577-581, 1997.

80. Szpirer C, Szpirer J, Tissir F, Stephanova E, Vanvooren P, Kurtz TW, Iwai N, Inagami T, Pravenec M, Kren V, Klinga Levan K, Levan G. Rat Chromosome 1: Regional localization of seven genes (SIc9a, Srd5n1, Esr, Tcp1, Grik5, Tnnt3, Jak2) and anchoring of the genetic linkage map to the cytogenetic map. Mammalian Genome 8:657-660, 1997.

- 81. Aitman T, Gotoda T, Evans AL, Imrie H, Heath KE, Trembling P, Truman H, Wallace CA, Rahman A, Doré C, Flint J, Kren V, Zidek V, Kurtz TW, Pravenec M, and Scott J. Quantitative trait loci for cellular defects in glucose & fatty acid metabolism in hypertensive rats. Nature Genetics 16:197-201, 1997.
- 82. Churchill PC, Churchill MC, Bidani AK, Griffin KA, Picken M, Pravenec M, Kren V, St. Lezin EM, Wang J, Wang N, Kurtz TW. Genetic susceptibility to hypertension-induced renal damage in the rat: Evidence based on kidney-specific genome transfer. Journal of Clinical Investigation 100: 1373-1382, 1997.
- 83. Kurtz TW, Gardner DG. Transcription modulating drugs: A new frontier in the treatment of essential hypertension. Hypertension, 32: 380-386, 1998.
- 84. Pravenec M, Krenová D, Kren V, Zídek V, Simáková M, Musilová A, Bottger A, Van Zutphen BF, St Lezin E, Kurtz TW. Congenic strains for genetic analysis of hypertension and dyslipidemia in the spontaneously hypertensive rat. Transplantation Proceedings 31:1555-1556, 1999.
- 85. Pravenec M, Zidek V, Simakova M, Kren V, Krenova D, Horky K, Jachymova M, Mikova B, Kazdova L, Aitman TJ, Churchill PC, Webb RC, Hingarh NH, Yang Y, Wang J, St. Lezin EM, and Kurtz TW. Genetics of Cd36 and the clustering of multiple cardiovascular risk factors in spontaneous hypertension. Journal of Clinical Investigation 103:1651-1657, 1999.
- 86. St. Lezin EM, Griffin KA, Picken M, Churchill MC, Churchill PC, Kurtz TW, Liu W, Wang N, Kren V, Zidek V, Pravenec M, Bidani AK. Genetic isolation of a chromosome 1 region affecting susceptibility to hypertension-induced renal damage in the spontaneously hypertensive rat. Hypertension 34:187-191, 1999.
- 87. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al-Majali KM, Trembling P, Mann CJ, Shoulders CC, Graf D, St. Lezin EM, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nature Genetics 21:76-83, 1999.
- 88. Benson S, Wu J, Padmanabhan S, Kurtz TW, Pershadsingh HA. Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone. Am J Hypertension 13(1 Pt 1):74-82, 2000.
- 89. Benson S, Padmanabhan S, Kurtz TW, Pershadsingh HA. Ligands for the peroxisome proliferator activated receptor gamma and the retinoid X receptor exert synergistic antiproliferative effects on human coronary artery smooth muscle cells. Molecular Cell Biology Research Communications 3:159-164, 2000.
- 90. Ellis CN, Varani J, Fisher G, Zeigler ME, Pershadsingh HA, Benson SC, Kurtz TW. Troglitazone improves psoriasis and normalizes models of proliferative skin disease:

- Ligands for peroxisome proliferator activated receptor gamma inhibit keratinocyte proliferation. Archives of Dermatology, 136:609-616, 2000.
- 91. St.Lezin E, Liu W, Wang, JM, Qi N, Kren V, Zidek V, Kurtz TW, Pravenec M. Genetic analysis of rat chromosome 1 and the Sa gene in spontaneous hypertension. Hypertension 35:225-230, 2000.
- 92. St.Lezin E, Liu W, Wang, JM, Qi N, Kren V, Zidek V, Kurtz TW, Pravenec M. Genetic analysis of rat chromosome 1 and the Sa gene in spontaneous hypertension. Hypertension 35:225-230, 2000.
- 93. Griffin KA, Churchill PC, Picken MA, Webb RC, Kurtz TW, Bidani AK. Differential salt-sensitivity in the pathogenesis of renal damage in SHR and stroke prone SHR. American Journal of Hypertension, 14(4 Pt 1):311-20, 2001.
- 94. Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kazdova L, Aitman TJ, Glazier AM, Ibrahimi A, Abumrad N, Qi N, Wang JM, St. Lezin E, Kurtz TW. Transgenic Rescue of Defective Cd36 Ameliorates Insulin Resistance and Circulating Fatty Acid Levels in Spontaneously Hypertensive Rats. Nature Genetics, 27:156-158, 2001.
- 95. Churchill PC, Churchill M, Bidani A, Kurtz TW. Kidney Specific Chromosome Transfer in Hypertension: The Dahl Hypothesis Revisited. Kidney International, 60(2):705-14, 2001.
- 96. Pravenec M, Jansa P, Kostka V, Zidek V, Kren V, Forejt J, Kurtz TW. Identification of a mutation in ADD1/SREBP-1 in the spontaneously hypertensive rat. Mammalian Genome Apr;12(4):295-298, 2001.
- 97. Pravenec MP, Zidek V, Musilova A, Vorlieek J, Kren V, St. Lezin E, Kurtz TW. Genetic Isolation of a blood pressure quantitative trait locus on chromosome 2 in the spontaneously hypertensive rat. Journal of Hypertension 19:1061-4. 2001.
- 98. Hajri T, Ibrahimi A, Coburn CT, Knapp FF Jr, Kurtz T, Pravenec M, Abumrad NA. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia and myocardial hypertrophy. J Biol Chem 276:23661-23666, 2001.
- 99. Bidani AK, Griffin KA, Churchill PC, Churchill MC, St. Lezin, EM, Kurtz, TW. Genetic susceptibility to renal injury in hypertension. Experimental Nephrology 9:360-365, 2001.
- 100. Pravenec M, Kurtz TW. Genetics of Cd36 and the Hypertension Metabolic Syndrome. Seminars in Nephrology 22:148-153, 2002.
- 101. Churchill PC, Churchill MC, Griffin KA, Picken M, Webb RC, Kurtz TW, Bidani AK. Increased genetic susceptibility to renal damage in the stroke-prone spontaneously hypertensive rat. Kidney Int. 61(5):1794-1800, 2002.
- 102. Pravenec M, Zidek V, Musilova A, Simakova M, Kostka V, Mlejnek P, Kren V, Krenova D, Bila V, Horky K, Kazdova L, St Lezin E, Kurtz TW. Genetic analysis of metabolic defects in the spontaneously hypertensive rat. Mammalian Genome 13(5):253-8, 2002.
- 103. Qi N, Kazdova L, Zidek V, Landa V, Kren V, Pershadsingh HA, Lezin ES, Abumrad NA, Pravenec M, Kurtz TW. Pharmacogenetic evidence that CD36 is a key determinant of the metabolic effects of pioglitazone. J Biol Chem. 13;277(50):48501-48507, 2002.
- 104. Pravenec M, Wallace C, Aitman T, Kurtz TW. Gene expression profiling in hypertension research: a critical perspective. Hypertension 41:3-8, 2003 (peer reviewed).

- 105. Kurtz TW: False claims of blood pressure independent protection by blockade of the renin angiotensin aldosterone system? Hypertension 2003; 41: 193-196 (peer reviewed)
- 106. Rao SP, McRae C, Lapanowski K, Churchill M, Kurtz TW, Dunbar JC. Insulin mediated hemodynamic responses in spontaneous hypertensive rats (SHRs): effect of chromosome 4 gene transfer. Clin Exp Hypertens 2003; 25:131-142.
- 107. Pravenec M, Kren V, Krenova D, Zidek V, Simakova M, Musilova A, Vorlicek J, Lezin ES, Kurtz TW. Genetic isolation of quantitative trait loci for blood pressure development and renal mass on chromosome 5 in the spontaneously hypertensive rat. Physiol Res 2003;52(3):285-291.
- 108. Mlejnek P, Kren V, Liska F, Zidek V, Landa V, Kurtz TW, Pravenec M. The CD36 protein functions as an immunogenic domain of the RT8 alloantigen. <u>Eur J Immunogenet</u>. 2003 Oct;30(5):325-7.
- 109. Pravenec M, Kazdová L, Landa V, Zídek V, Mlejnek P, Jansa P, Wang J, Qi N, Kurtz TW. Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. Journal of Biological Chemistry 2003 278(46):45209-15.
- 110. Pravenec M, Landa V, Zidek V, Musilova A, Kazdova L, Qi N, Wang J, Lezin ES, Kurtz TW. Transgenic expression of CD36 in the spontaneously hypertensive rat is associated with amelioration of metabolic disturbances but has no effect on hypertension. Physiol Res. 2003;52(6):681-8.
- 111. Pershadsingh HA and Kurtz TW. Insulin sensitizing effects of telmisartan. Diabetes Care 2004; 27:1015.
- 112. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARy modulating activity. Hypertension, 2004;43:993-1002.
- 113. Bhagavathula N, Nerusu KC, Lal A, Ellis CN, Chittiboyina A, Avery MA, Ho Cl, Benson SC, Pershadsingh HA, Kurtz TW, Varani J. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol. 2004 Jan;122(1):130-9.117.
- 114. Patel SN, Serghides L, Smith TG, Febbraio M, Silverstein RL, Kurtz TW, Pravenec M, Kain KC. CD36 mediates the phagocytosis of Plasmodium falciparum-infected erythrocytes by rodent macrophages. J Infect Dis. 2004 Jan 15;189(2):204-13.
- 115. Venkatraman MS, Chittiboyina A, Meingassner J, Ho CI, Varani J, Ellis CN, Avery MA, Pershadsingh HA, Kurtz TW, Benson SC. alpha-Lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases. Arch Dermatol Res. 2004 Aug;296(3):97-104.
- 116. Meyer B, Bazzi H, Zidek V, Musilova A, Pravenec M, Kurtz TW, Nurnberg P, Christiano AM. A spontaneous mutation in the desmoglein 4 gene underlies hypotrichosis in a new lanceolate hair rat model. Differentiation. 2004 Dec;72(9-10):541-7.
- 117. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004 Dec;22(12):2253-2261.
- 118. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for

professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005 Jan;45(1):142-161.

- 119. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurement in humans and experimental animals: part 2: blood pressure measurement in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005 Feb;45(2):299-310.
- 120. Hubner N, Wallace CA, Zimdahl H, Petretto E, Schulz H, Maciver F, Mueller M, Hummel O, Monti J, Zidek V, Musilova A, Kren V, Causton H, Game L, Born G, Schmidt S, Muller A, Cook SA, Kurtz TW, Whittaker J, Pravenec M, Aitman TJ. Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Nature Genetics 2005 Mar;37:243-253.
- 121. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol, 2005 Apr;42 Suppl 1:S9-16.
- 122. Qi N, Wang J, Zidek V, Landa V, Mlejnek P, Kazdová L, Pravenec M, Kurtz TW. A New transgenic rat model of hepatic steatosis and the metabolic syndrome. Hypertension, 2005 May;45(5):1004-11.
- 123. Bhagavathula N, Nerusu KC, Reddy M, Ellis CN, Chittiboyina A, Avery M, Pershadsingh HA, Kurtz TW, Varani J. BP-1107: A novel, synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin SCID mouse transplants following topical application. J Pharmacol Exp Ther. 2005; 315(3):996-1004.
- 124. Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. American Journal of Medicine, 2006 May;119(5 Suppl 1):S24-30.
- 125. Chittiboyina AG, Venkatraman MS, Mizuno CS, Desai PV, Patny A, Benson SC, Ho CI, Kurtz TW, Pershadsingh HA, Avery MA. Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists. J Med Chem, 2006 Jul 13;49(14):4072-84.
- 126. Pravenec M, Kazdova L, Cahova M, Landa V, Zidek V, Mlejnek P, Simakova M, Wang J, Qi N, Kurtz TW. Fat-specific transgenic expression of resistin in the spontaneously hypertensive rat impairs fatty acid re-esterification. Int J Obes (Lond). 2006 Jul;30(7):1157-9.
- 127. Pravenec M and Kurtz TW. Molecular genetics of experimental hypertension and the metabolic syndrome: From gene pathways to new therapies. Hypertension. 2007 May 49:941-52.
- 128. Pravenec M, Hyakukoku M, Houstek J, Zidek V, Landa V, Mlejnek P, Miksik I, Dudova-Mothejzikova K, Pecina P, Vrbacky M, Drahota Z, Vojtiskova A, Mracek T, Kazdova L, Oliyarnyk O, Wang J, Ho C, Qi N, Sugimoto K, Kurtz T. Direct linkage of mitochondrial genome variation to risk factors for type 2 diabetes in conplastic strains. Genome Research. 2007 Sep;17(9):1319-26.
- 129. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA. Type 2 diabetes and oral antihyperglycemic drugs. Current Medicinal Chemistry 2008; 15:61-74.

- 130. Benson SC, Iguchi R, Ho CI, Yamamoto K, Kurtz TW. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertension 2008 May;26(5):973-80.
- 131. Sugimoto K, Kazdová L, Qi NR, Hyakukoku M, K?en V, Simáková M, Zídek V, Kurtz TW, Pravenec M. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J Hypertension 2008:;26:1209-1215.
- 132. Kurtz TW and Pravenec M. Molecule Specific Effects of Angiotensin II Receptor Blockers Independent of the Renin Angiotensin System. <u>American Journal of Hypertension</u>, 2008; 21:852-859.
- 133. Kurtz TW. Beyond the classic angiotensin-receptor-blocker profile. Nature Clinical Practice Cardiovasc Med. 2008 Jul;5 Suppl 1:S19-26.
- 134. Pravenec M, Kazdova L, Landa V, Zidek V, Mlejnek P, Simakova M, Jansa P, Forejt J, Kren V, Krenova D, Qi N, Wang JM, Chan D, Aitman TJ, Kurtz TW. Identification of mutated Srebf1 as a QTL influencing risk for hepatic steatosis in the spontaneously hypertensive rat. Hypertension 2008; 51:148-153.
- 135. Petretto E, Sarwar R, Grieve I, Lu H, Kumaran MK, Muckett PJ, Mangion J, Schroen B, Benson M, Punjabi PP, Prasad SK, Pennell DJ, Kiesewetter C, Tasheva ES, Corpuz LM, Webb MD, Conrad GW, Kurtz TW, Kren V, Fischer J, Hubner N, Pinto YM, Pravenec M, Aitman TJ, Cook SA. Integrated genomic approaches implicate osteoglycin (Ogn) in the regulation of left ventricular mass. Nature Genetics 2008; 40(5):546-552.
- 136. Pravenec M, Churchill PC, Churchill MC, Viklicky O, Kazdova L, Aitman TJ, Petretto E, Hubner N, Wallace CA, Zimdahl H, Zidek V, Landa V, Dunbar J, Bidani A, Griffin K, Qi N, Maxova M, Kren V, Mlejnek P, Wang J, Kurtz TW. Identification of renal Cd36 as a determinant of blood pressure and risk for hypertension. Nature Genetics, 2008; 40(8):952-954.
- 137. Pravenec M, Kazdová L, Maxová M, Zídek V, Mlejnek P, Simáková M, Kurtz TW. Longterm pioglitazone treatment enhances lipolysis in rat adipose tissue. International Journal of Obesity, 2008; 32(12):1848-53.
- 138. Johnson MD, He L, Herman D, Wakimoto H, Wallace CA, Zidek V, Mlejnek P, Musilova A, Simakova M, Vorlicek J, Kren V, Viklicky O, Qi NR, Wang J, Seidman CE, Seidman J, Kurtz TW, Aitman TJ, Pravenec M. Dissection of chromosome 18 blood pressure and salt-sensitivity quantitative trait loci in the spontaneously hypertensive rat. Hypertension, 2009; 54:639-45.
- 139. Design, synthesis, and docking studies of telmisartan analogs for the treatment of metabolic syndrome. Mizuno CS, Chittiboyina AG, Patny A, Kurtz TW, Pershadsingh HA, Speth RC, Karamyan VT, Avery MA. Medicinal Chemistry Research, 2009; 8:611-628.
- 140. Kurtz TW and Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertension Research, 2009; 32:826-34.
- 141. Yamamoto K, Ohishi M, Ho C, **Kurtz TW**, Rakugi H. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation. Hypertension, 2009 Dec;54(6):1353-9.
- 142. Malínská H, Oliyarnyk O, Hubová M, Zídek V, Landa V, Simáková M, Mlejnek P, Kazdová L, **Kurtz TW**, Pravenec M. Increased liver oxidative stress and altered PUFA metabolism

- precede development of non-alcoholic steatohepatitis in SREBP-1a transgenic spontaneously hypertensive rats with genetic predisposition to hepatic steatosis. Mol Cell Biochem. 2010; 335:119-125.
- 143. Pravenec M and **Kurtz TW**. Recent advances in the genetics of the spontaneously hypertensive rat. <u>Current Hypertension Reports</u>, 2010; 12:5-9
- 144. Pi J, Leung L, Xue P, Wang W, Hou Y, Liu D, Yehuda-Shnaidman E, Lee C, Lau J, **Kurtz TW**, Chan J. Deficiency in the Nrf2 transcription factor results in impaired adipogenesis and protects against diet-induced obesity. <u>Journal of Biological Chemistry</u>, 2010; 19;285(12):9292-300.
- 145. **Kurtz TW**. Chlorthalidone: Don't call it "thiazide-like" anymore. <u>Hypertension</u>, 2010; 56:335-337 (peer reviewed).
- 146. **Kurtz TW**. Genome wide association studies will not unlock the genetics of hypertension. <u>Hypertension</u>, 2010;56:1021-1025.
- 147. Atanur SS, Birol I, Guryev V, Hirst M, Hummel O, Morrissey C, Behmoaras J, Fernandez-Suarez XM, Johnson MD, McLaren WM, Patone G, Petretto E, Plessy C, Rockland KS, Rockland C, Saar K, Zhao Y, Carninci P, Flicek P, **Kurtz TW**, Cuppen E, Pravenec M, Hubner N, Jones SJ, Birney E, Aitman TJ. The genome sequence of the spontaneously hypertensive rat: Analysis and functional significance. <u>Genome Research</u>. 2010; 20(6):791-803.
- 148. Tocci G, Paneni F, Palano F, Sciarretta S, Ferrucci A, **Kurtz T**, Mancia G, Volpe M. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials. <u>American Journal of Hypertension</u>. 2011; 24(5):582-90.
- 149. Pravenec M, Zidek V, Landa V, Simakova M, Mlejnek P, Silhavy J, Maxova M, Kazdova L, Seidman JG, Seidman CE, Eminaga S, Gorham J, Wang J, **Kurtz TW** Age-related autocrine diabetogenic effects of transgenic resistin in spontaneously hypertensive rats: gene expression profile analysis. <a href="https://press.org/Physiological Genomics">Physiological Genomics</a>. 2011; 43(7):372-379.
- 150. Pravenec M, Kajiya T, Zídek V, Landa V, Mlejnek P, Simáková M, Silhavy J, Malínská H, Oliyarnyk O, Kazdová L, Fan J, Wang J, Kurtz TW. Effects of Human C-Reactive Protein on Pathogenesis of Features of the Metabolic Syndrome. <u>Hypertension</u>. 2011; 57(4):731-7. SELECTED TOP PAPER IN THE BASIC SCIENCE CATEGORY FOR PUBLICATION YEAR 2011 IN HYPERTENSION JOURNAL
- 151. Kajiya T, Ho C, Wang J, Vilardi R, **Kurtz TW**. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. <u>J Hypertension</u>. 2011; 29:2476-83.
- 152. Neckar J, Silhavy J, Zidek V, Landa V, Mlejnek P, Simakova M, Seidman JG, Seidman CE, Kazdova L, Klevstig M, Novak F, Vecka M, Papousek F, Houstek J, Drahota Z, Kurtz TW, Kolar F, Pravenec M. CD36 overexpression predisposes to arrhythmias but reduces infarct size in spontaneously hypertensive rats: gene expression profile analysis. <a href="Physiological Genomics.">Physiological Genomics.</a> 2012;44:173-82. PMID 22128087
- 153. **Kurtz TW**, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. <u>Vascular Health and Risk Management</u>. 2012;8:133-43. PMID: 22399858
- 154. Houstek J, Hejzlarova K, Vrbacky M, Drahota Z, Landa V, Zidek V, Mlejnek P, Simakova M, Silhavy J, Miksik I, Kazdova L, Oliyarnyk O, **Kurtz TW**, Pravenec M. Non-synonymous variants in mt-Nd2, mt-Nd4, and mt-Nd5 are linked to effects on oxidative phosphorylation

- and insulin sensitivity in rat conplastic strains. <u>Physiological Genomics</u>. 2012, 44:487-494. PMID: 22414913
- 155. Takeuchi K, Yamamoto K, Ohishi M, Takeshita H, Hongyo K, Kawai T, Takeda M, Kamide K, **Kurtz TW**, Rakugi H. Telmisartan modulates mitochondrial function in vascular smooth muscle cells. <u>Hypertension Research</u>. 2013 May;36(5):433-9 PMID: 23254392
- 156. Pravenec M, Ko⊡ich V, Krijt J, Sokolová J, ZídekV, Landa V, Šimáková M, Mlejnek P, Šilhavý J, Oliyarnyk O, Kazdová L, **Kurtz TW**. Folate deficiency is associated with oxidative stress, increased blood pressure, and insulin resistance in spontaneously hypertensive rats. <u>American Journal of Hypertension</u>. 2013;26:135-140
- 157. Zídek V, Mlejnek P, Simáková M, Silhavy J, Landa V, Kazdová L, Pravenec M, **Kurtz TW**. Tissue-Specific Peroxisome Proliferator Activated Receptor Gamma Expression and Metabolic Effects of Telmisartan. <u>American Journal of Hypertension</u>. 2013;26:829-835. PMID 23426788
- 158. **Kurtz TW**. When blockade of the renin-angiotensin system becomes a two-edged sword. American J Hypertension. 2013 Jun;26(6):721-2. PMID:23564251
- 159. Woeber KA, White A, **Kurtz TW**. Recurrent Pituitary Macroadenoma with Increased Plasma ACTH Precursors that Cross React in a Commonly Used ACTH Immunoassay. <u>Endocrine Practice</u>. 2013 Oct 14:1-7
- 160. Silhavý J, Zídek V, Landa V, Simáková M, Mlejnek P, Skop V, Oliyarnyk O, Kazdová L, Mancini M, Saar K, Schulz H, Hübner N, Kurtz TW, Pravenec M. Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels. <u>Cardiovascular Therapeutics</u>. 2014 Apr;32(2):59-65. doi: 10.1111/1755-5922.12061.
- 161. **Kurtz TW**, Lujan HL, DiCarlo SE. The 24 h pattern of arterial pressure in mice is determined mainly by heart rate-driven variation in cardiac output. <u>Physiol Rep</u>. 2014 Nov 1; 2(11). PMID: 25428952.
- 162. Houstek J, Vrbacky M, Hejzlarova K, Zidek V, Landa V, Silhavy J, Simakova M, Mlejnek P, Kazdova L, Miksik I, Neckar J, Papousek F, Kolar F, Kurtz TW, Pravenec M. Effects of mtDNA in SHR-mtF344 versus SHR conplastic strains on reduced OXPHOS enzyme levels, insulin resistance, cardiac hypertrophy, and systolic dysfunction. <a href="Physiological Genomics">Physiological Genomics 2014. 46:671-678. PMID 25073601</a>
- 163. **Kurtz TW**, Dominiczak AF, DiCarlo SE, Pravenec M, Morris RC. Molecular-based mechanisms of mendelian forms of salt-dependent hypertension: questioning the prevailing theory. Hypertension. 2015 May; 65(5):932-41. PMID: 25753977
- 164. Yamamoto K, Kakino A, Takeshita H, Hayashi N, Li L, Nakano A, Hanasaki-Yamamoto H, Fujita Y, Imaizumi Y, Toyama-Yokoyama S, Nakama C, Kawai T, Takeda M, Hongyo K, Oguro R, Maekawa Y, Itoh N, Takami Y, Onishi M, Takeya Y, Sugimoto K, Kamide K, Nakagami H, Ohishi M, **Kurtz TW**, Sawamura T, Rakugi H. Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin-like oxLDL receptor. <u>FASEB J</u>. 2015 Aug; 29(8):3342-56. PMID: 25877213
- 165. Pravenec M, Landa V, Zídek V, Mlejnek P, Šilhavý J, Mir SA, Vaingankar SM, Wang J, Kurtz TW. Effects of transgenic expression of dopamine beta hydroxylase (Dbh) gene on blood pressure in spontaneously hypertensive rats. <a href="Physiological Research">Physiological Research</a>. 2016 Dec 13;65(6):1039-1044

- 166. Pravenec M, Ko ich V, Krijt J, Sokolová J, Zídek V, Landa V, Mlejnek P, Šilhavý J, Šimáková M, Škop V, Trnovská J, Kazdová L, Kajiya T, Wang J, Kurtz TW. Genetic Variation in Renal Expression of Folate Receptor 1 (Folr1) Gene Predisposes Spontaneously Hypertensive Rats to Metabolic Syndrome. <u>Hypertension</u>. 2016 Feb; 67(2):335-41. PMID: 26667416
- 167. Schneider K, Valdez J, Nguyen J, Vawter M, Galke B, **Kurtz TW**, Chan JY. Increased energy expenditure, UCP1 expression and resistance to diet-induced obesity in mice lacking nuclear factor-erythroid-2 related transcription factor-2 (Nrf2). <u>J Biol Chem</u>. 2016 Apr 1;291(14):7754-66. PMID:26841864
- 168. Morris RC Jr, Schmidlin O, Sebastian A, Tanaka M, Kurtz TW. Vasodysfunction that involves renal vasodysfunction, not abnormally increased renal retention of sodium, accounts for the initiation of salt-induced hypertension. <u>Circulation</u>. 2016 Mar 1;133(9):881-93. PMCID PMC4778403
- 169. **Kurtz TW**, DiCarlo SE, Pravenec M, Schmidlin O, Tanaka M, Morris RC Jr. An alternative hypothesis to the widely held view that renal excretion of sodium accounts for resistance to salt-induced hypertension <u>Kidney International</u>. 2016 Nov;90(5):965-973. PMID: 27546606
- 170. **Kurtz TW**, DiCarlo SE, Morris RC. Logical issues with the pressure natriuresis theory of chronic hypertension. <u>American Journal of Hypertension</u>. 2016;29(12):1325-1331. PMID: 28637271
- 171. **Kurtz TW**, DiCarlo SE, Pravenec M, Morris RC Jr. An appraisal of methods recently recommended for testing salt sensitivity of blood pressure. <u>Journal of the American Heart Association</u>. 2017 Apr 1;6(4). pii: e0056532017. PMID: 28365569
- 172. **Kurtz TW**, DiCarlo SE, Pravenec M, Morris RC Jr. The American Heart Association Scientific Statement on salt sensitivity of blood pressure: Prompting consideration of alternative conceptual frameworks for the pathogenesis of salt sensitivity? <u>Journal of Hypertension</u>. 2017 Nov;35(11):2214-2225. PMID: 28650918
- 173. **Kurtz TW**, DiCarlo SE, Pravenec M, Morris RC, Jr. The pivotal role of renal vasodysfunction in salt sensitivity and the initiation of salt-induced hypertension. <u>Current Opinion in Nephrology and Hypertension</u>. 2018; 27(2):83-92. PMID 29278541
- 174. **Kurtz TW**, DiCarlo SE, Pravenec M, Morris RC, Jr. Functional foods for augmenting nitric oxide activity and reducing the risk for salt-induced hypertension and cardiovascular disease in Japan. J Cardiol. 2018; 72:42-49. PMID:29544657
- 175. **Kurtz TW**, DiCarlo SE, Pravenec M, Morris RC, Jr. Changing views on the common physiologic abnormality that mediates salt sensitivity and initiation of salt-induced hypertension: Japanese research underpinning the vasodysfunction theory of salt sensitivity. Hypertension Research. 2018: 42:6-18. PMID 30390036
- 176. **Kurtz TW**, DiCarlo SE, Pravenec M, Jezek F, Silar, J, Kofranek J, Morris RC, Jr. Testing computer models predicting human responses to a high salt diet: Implications for understanding mechanisms of salt sensitive hypertension. <u>Hypertension</u>. 2018; 72(6):1407-1416. PMID:30571226
- 177. Šilar J, Polák D, Mládek A, Je⊡ek F, **Kurtz TW**, DiCarlo SE, □ivný J, Kofranek J. Development of In-Browser Simulators for Medical Education: Introduction of a Novel Software Toolchain. <u>J Med Internet Research</u> 2019;21(7):e14160. PMID: 31271154

- 178. Morris RC, Pravenec M. Silhavy J, DiCarlo SE, **Kurtz TW**. Small amounts of inorganic nitrate or beetroot provide substantial protection from salt-induced increases in blood pressure. <u>Hypertension</u>. 2019; 73:1042-1048. PMID: 30917704
- 179. Lerman LO, **Kurtz TW**, Touyz RM, Ellison DH, Chade AR, Crowley SD, Mattson DL, Mullins JJ, Osborn J, Eirin A, Reckelhoff JF, Iadecola C, Coffman TM. Animal Models of Hypertension: A Scientific Statement From the American Heart Association. <u>Hypertension</u>. 2019;73:e87-e120. PMID: 30866654
- 180. **Kurtz TW**, Pravenec M, DiCarlo SE. Strategies are needed to prevent salt-induced hypertension that do not depend on reducing salt intake. <u>American Journal of Hypertension</u>. 2020; 116-118 (peer reviewed). PMID: 31634913
- 181. Ng DL, Goldgof GM, Shy BR, Levine AG, Balcerek J, Bapat SP, Prostko J, Rodgers M, Coller K, Pearce S, Franz S, Du L, Stone M, Pillai SK, Sotomayor-Gonzalez A, Servellita V, Martin CSS, Granados A, Glasner DR, Han LM, Truong K, Akagi N, Nguyen DN, Neumann NM, Qazi D, Hsu E, Gu W, Santos YA, Custer B, Green V, Williamson P, Hills NK, Lu CM, Whitman JD, Stramer SL, Wang C, Reyes K, Hakim JMC, Sujishi K, Alazzeh F, Pham L, Thornborrow E, Oon CY, Miller S, Kurtz T, Simmons G, Hackett J, Busch MP, Chiu CY. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood. Nat Commun. 2020 09 17; 11(1):4698. PMID: 32943630. PMCID: PMC7499171
- 182. Wang RC, Murphy CE, Kornblith AE, Kurtz T, Kohn MA. Prevalence of SARS-Cov-2 Antibodies in Emergency Medicine Healthcare Workers. <u>Ann Emerg Med</u>. 2021 05; 77(5):556-557. PMID: 33902837. PMCID: PMC7799153
- 183. **Kurtz TW**, DiCarlo SE, Pravenec M, Morris RC. No evidence of racial disparities in blood pressure salt sensitivity when potassium intake exceeds levels recommended in the US dietary guidelines. <u>Am J Physiol Heart Circ Physiol</u>. 2021 05 01; 320(5):H1903-H1918. PMID: 33797275. PMCID: PMC8163653
- 184. Peluso MJ, Takahashi S, Hakim J, Kelly JD, Torres L, Iyer NS, Turcios K, Janson O, Munter SE, Thanh C, Donatelli J, Nixon CC, Hoh R, Tai V, Fehrman EA, Hernandez Y, Spinelli MA, Gandhi M, Palafox MA, Vallari A, Rodgers MA, Prostko J, Hackett J, Trinh L, Wrin T, Petropoulos CJ, Chiu CY, Norris PJ, DiGermanio C, Stone M, Busch MP, Elledge SK, Zhou XX, Wells JA, Shu A, **Kurtz TW**, Pak JE, Wu W, Burbelo PD, Cohen JI, Rutishauser RL, Martin JN, Deeks SG, Henrich TJ, Rodriguez-Barraquer I, Greenhouse B. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv. 2021 Jul; 7(31). PMID: 34330709. PMCID: PMC8324059
- 185. Grant M, Harrison R, Nunez A, **Kurtz T**, Phelps S, Brokaw J, Shusterman D. Seroprevalence of SARS-CoV-2 among firefighters/paramedics in San Francisco. <u>J Occup Environ Med.</u> 2021 Nov;63(11):e807-e812. PMID: 34739446 PMCID: PMC8562912
- 186. Wang RC, Murphy CE, Kornblith AE, Hoehnstein NA, Carter CM, Wong, AHD, Kurtz T, Kohn MA. SARS-COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 April 2021. <u>Am J Emerg Med</u>. 2022 Apr; 54:81-86. PMID: 35144108. PMCID: PMC8808429
- 187. **Kurtz TW**, Pravenec M, DiCarlo SE. Will Food and Drug Administration guidance to reduce the salt content of processed foods reduce salt intake and save lives? <u>Hypertension</u>. 2022 Apr; 79(4):809-812 (peer reviewed). PMID: 35263161 PMCID: PMC8903218

188. **Kurtz TW**, Pravenec M, DiCarlo SE. Mechanism-based strategies to prevent salt sensitivity and salt-induced hypertension. <u>Clinical Science</u>. 2022 Apr 29;136(8):599-620. doi: 10.1042/CS20210566. PMID: 35452099

189. **Kurtz TW**, Morris RC, Pravenec M, Lujan H, DiCarlo SE. Hypertension in Primary Aldosteronism Is Initiated by Salt-Induced Increases in Vascular Resistance With Reductions in Cardiac Output. <u>Hypertension</u>. 2023; May;80(5):1077-1091. doi: 0.1161/HYPERTENSIONAHA.123.20953

### **NON-PEER REVIEWED PUBLICATIONS**

1. REVIEW ARTICLES/COMMENTARIES, BOOK CHAPTERS, AND LETTERS

#### **REVIEW ARTICLES**

- 1. Kurtz TW. Renin gene polymorphisms and hypertension. ACE Reports, 75:1-4, 1991
- 2. **Kurtz TW**. Molecular Genetics News and Views: An ACE for Hypertension. <u>Nature</u> 353:499, 1991
- 3. **Kurtz TW.** Molecular Genetics News and Views: Myocardial Infarction: The ACE of Hearts. <u>Nature</u>, 359:588-589, 1992
- 4. **Kurtz TW**. Transgenic models of hypertension: Useful tools or unusual toys? <u>Journal of Clinical Investigation</u>, 91:741, 1993
- 5. Catanzaro D, **Kurtz TW**. New frontiers in aldosterone/mineralocorticoid biology: a reemerging force in target organ damage and hypertension. <u>American Journal of Hypertension</u>. 2001 Dec;14(12):1276-7.
- Catanzaro DF, Kurtz TW. Target organ damage in hypertension: mechanisms, prevention, and management. <u>American Journal of Hypertension</u>. 2002 Dec;15(12):1117-8
- 7. **Kurtz TW**. A vaccine for hypertension ? International Society of Hypertension Newsletter, volume 16, page 3, April, 2008

### **BOOKS AND CHAPTERS**

- Kurtz TW, Morris RC Jr: Dietary chloride as a determinant of "sodium-dependent" hypertension and hypercalciuria. In: <u>Proc of NIH Workshop on Nutrition and Hypertension</u>, pp 137-145, Biomed Information Co. New York, 1985
- Morris RC, Kurtz TW: Vitamin D, calcium, and hypertension. In: <u>Vitamin D 1988</u>, <u>Chemical. Biochemical, and Clinical Update</u>. A.W. Norman, K. Schaefer, H.G. Grigoleit, D.V. Herrath, eds. New York, NY Walter de Gruyter Publishing Co., 1988
- 3. **Kurtz TW**, Morris RC: Chloride as a determinant of salt-sensitivity. In: <u>Salt and Hypertension</u>. R. Rettig, D. Ganten, F. Luft, eds., Heidelberg, Springer Verlag, 1989
- 4. Morris RC, Al-Bander HA, **Kurtz TW**: Role of dietary chloride in hypertension. In: <u>Hypertension: Pathophysiologv. Diagnosis, and Management.</u> JH Laragh and BM Brenner, eds., New York, Raven Press, 1989

- 5. **Kurtz TW**, Simonet L, Kren V, Pravenec M. Gene mapping in experimental hypertension. In: Genetic Approaches for the Prevention and Control of Coronary Artery Diseases and Hypertension. Springer-Verlag, 1991
- 6. **Kurtz TW**, St.Lezin EM, Pravenec M. Development of Hypertension Models. In: <u>Textbook of Hypertension</u>. J. W. Swales, ed. Blackwell Scientific Publications, Oxford. 1994
- 7. **Kurtz TW**. Possible genetic lesions in experimental and clinical forms of essential hypertension. In: <a href="https://example.com/Hypertension"><u>Hypertension: Pathophysiology, Diagnosis, and Management.</u></a>. JH Laragh and BM Brenner, eds., New York, Raven Press, 1994
- 8. Krege J, **Kurtz TW**, Smithies O,. Using animal models to dissect the genetics of complex traits. In: <u>Molecular Genetics and Gene Therapy of Cardiovascular Diseases</u>. S. Mockrin, ed. Marcel Dekker, New York, 1996
- 9. **Kurtz TW**, Pravenec M, St. Lezin EM, Mellon SH. Molecular Genetics of Steroid Biosynthesis in Dahl Salt-Sensitive and Salt-Resistant Rats: Linkage to the Control of Blood Pressure. In: Molecular Genetics of Hypertension. A.F. Dominiczak, J.M.C. Connell, and F. Sourbrier, eds. Bios Scientific Publishers, Oxford, 1999.
- Churchill PC, Churchill MC, Bidani AK, Griffin KA, Picken M, Pravenec M, Kren V, St. Lezin EM, Kurtz TW. Mapping nephropathy susceptibility genes using kidney specific chromosome transfer. In: <u>Common Disease - Genetic and Pathogenetic Aspects of Multifactorial Diseases</u>, H. Imura, M. Kasuga, K. Nakao, eds. Excerpta Medica, Amsterdam, 1999
- 11. **Kurtz TW**. The antidiabetic effect of angiotensin II antagonists: evidence, mechanisms and clinical significance. In, <u>Angiotensin II Receptor Antagonists in Clinical Perspective</u> [2nd ed],, edited by G. Mancia, 2006
- 12. Tomino Y, Cooper ME, **Kurtz TW**, ShimizuY. Experimental Models of Type-2 Diabetic Nephropathy. In: <u>Experimental Diabetes Research</u>, Article ID 218917,. doi:10.1155/2012/218917, 2012

#### OTHER PUBLICATIONS

- 1. Kurtz TW, Morris RC Jr: Hypertension and sodium salts. Science 228:352-353, 1985
- Pershadsingh HA, Kurtz TW: Insulin resistance and hypertension. N EnglJ Med, 318:383-384, 1988
- 3. **Kurtz TW**, DiCarlo SE, Morris RC Jr. Response to Tautological Nature of Guyton's Theory of Blood Pressure Control. <u>Am J Hypertens</u>. 2017 Jul 1;30(7):e6. PMID: 28407048
- Kurtz TW, Morris RC Jr. What abnormalities initiate salt-induced increases in blood pressure according to the autoregulation and vasodysfunction theories for salt sensitivity? <u>Kidney Int</u>. 2017 Oct;92(4):1015-1016. PMID:28938938

# **PATENTS ISSUED OR PENDING**

- 1. Pershadsingh HA, *Kurtz TW*. Thiazolidine Derivatives for the Treatment of Hypertension. U.S. Patent No. 5,053,420, issued October 1, 1991
- 2. *Kurtz TW*, Pershadsingh HA. Thiazolidine Derivatives for the Treatment of Psoriasis. U.S. Patent No. 5,594,015, issued January 14, 1997

- 3. *Kurtz TW*, Pershadsingh HA. Thiazolidine Derivatives for the Treatment of Psoriasis (Acne). U.S. Patent No. 5,824,694, issued October 20, 1998
- 4. Pershadsingh HA, *Kurtz TW*. Thiazolidine Derivatives for the Treatment of Hypertension (Pioglitazone). U. S. Patent No. 5,843, 970, issued 12/01/98
- 5. Pershadsingh HA, *Kurtz TW*. Calcium Antagonists for the Treatment of Vascular Restenosis. U.S. Patent No. 5,866,595, issued February 2, 1999
- 6. Pershadsingh HA, *Kurtz TW*. Thiazolidine Derivatives for the Treatment of Hypertension (troglitazone related compounds). U.S. Patent No. 6,110,951, issued 8/29/00